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Abstract 
The genetic mechanisms that determine the size of the adult pancreas are poorly understood. 
Imprinted genes, which are expressed in a parent-of-origin-specific manner, are known to have 
important roles in development, growth and metabolism. However, our knowledge regarding their 
roles in the control of pancreatic growth and function remains limited. Here we show that many 
imprinted genes are highly expressed in pancreatic mesenchyme-derived cells and explore the role of 
the paternally-expressed insulin-like growth factor 2 (Igf2) gene in mesenchymal and epithelial 
pancreatic lineages using a newly developed conditional Igf2 mouse model. Mesenchyme-specific Igf2 
deletion results in acinar and beta-cell hypoplasia, postnatal whole-body growth restriction and 
maternal glucose intolerance during pregnancy, suggesting that the mesenchyme is a developmental 
reservoir of IGF2 used for paracrine signalling. The unique actions of mesenchymal IGF2 are 
demonstrated by the absence of any discernible growth or functional phenotypes upon Igf2 deletion 
in the developing pancreatic epithelium. Additionally, increased IGF2 levels specifically in the 
mesenchyme, through conditional Igf2 loss-of-imprinting or Igf2r deletion, leads to pancreatic acinar 
overgrowth. Furthermore, ex-vivo exposure of primary acinar cells to exogenous IGF2 activates AKT, 
a key signalling node, and increases their number and amylase production. Based on these findings, 
we propose that mesenchymal Igf2, and perhaps other imprinted genes, are key developmental 
regulators of adult pancreas size and function. 
 
Author summary 
The pancreas is formed of two main components: the exocrine pancreas (producing digestive enzymes 
that break down food so it can be easily absorbed by the intestine) and the endocrine pancreas 
(producing insulin and other hormones that control blood sugar levels). Additionally, the pancreas 
contains stromal cells (mesenchyme-derived cells) that support the function of the exocrine and 
endocrine components. We know little about how the pancreas reaches its normal size. In this study, 
using mouse genetic engeneering, we explored the roles played by a hormone-like gene called Igf2, 
that is similar in structure to insulin, and is active only on the chromosome inherited from the father. 
We found that within the pancreas, Igf2 is mostly active in the mesenchyme-derived cells. When Igf2 
is lost specifically within these cells, the entire pancreas becomes smaller, with reduced capacity to 
produce digestive enzymes and to maintain normal blood sugar levels during pregnancy. Increased 
IGF2 levels in the mesenchyme-derived cells leads to a larger pancreas, while no effects are observed 
when Igf2 is lost in the exocrine and endocrine pancreas. Our results demonstrate that Igf2 activity in 
mesenchyme-derived cells is key for the control of pancreas size and function. 
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Introduction  
The mammalian pancreas plays a central role in energy homeostasis, which is achieved by functionally 
and morphologically distinct exocrine and endocrine components. Optimal pancreatic function 
requires a match between pancreas size and the physiological demands of the host organism. 
However, the genetic determinants of organ size, and the mechanisms that achieve adequate relative 
organ size, are poorly understood. The size of the pancreas is thought to be fixed early in development, 
limited by the size of the progenitor cell pool that is established in the developing pancreatic bud [1]. 
In addition to autonomous cues in the epithelium, pancreatic development is also dictated by non-
autonomous signals from the mesenchyme. Mesenchymal cells overlie the developing pancreatic bud 
and provide critical signals for the expansion of both precursors and differentiated endocrine and 
exocrine cells [2]. These cells are present throughout pancreas organogenesis, but the relative 
proportion of mesenchyme to epithelium changes, with a dramatic reduction over time, as the 
mesenchyme differentiates into more specialized cell types such as pericytes [3] and epithelial cells 
expand. Recent elegant genetic manipulation approaches in the mouse have shown that mesenchymal 
cells regulate pancreatic growth and branching at both early and late in utero developmental stages 
[2,4]. However, many of the mesenchymal signals that control these processes remain un-identified. 
Moreover, the factors required for cell fate decisions that specify individual pancreas cell type subsets 
are fairly well established but less is known about signalling pathways involved in proliferation and 
survival of cell types.  
Insulin-like growth factors (IGF1 and IGF2) are small mitogenic polypeptides (~7KDa) with structural 
homology to pro-insulin. IGF2 is also a pro-survival factor, protecting against apoptosis [5–7]. Although 
IGF expression is ubiquitous in many cell types, they are most abundant in the cells and tissues of 
mesodermal origin, and form important components of stem cell niches [8–13]. Igf2 transcription is 
regulated by genomic imprinting [14], an epigenetic process that causes a subset of genes in the 
genome to be transcribed according to parental origin. Imprinted genes regulate key aspects of 
mammalian physiology, from growth to energy homeostasis [15]. In most mouse and human tissues, 
Igf2 is only transcribed from the paternally inherited allele, with the maternal allele being repressed 
by a methylation sensitive CTCF-dependent boundary that restricts the access of downstream 
enhancers to the Igf2 gene promoters [16]. In humans, reduced Igf2 expression contributes to the 
intra-uterine growth restriction in patients with Silver-Russell syndrome [17]. Conversely, bialellic Igf2 
expression caused by loss of Igf2 imprinting is observed in Beckwith-Wiedemann patients [18], a 
syndrome characterized by somatic overgrowth, neonatal hypoglycaemia with variable penetrance 
and increased predisposition to tumours. In mice, increased supply of embryonic Igf2 above biallelic 
expression can result in disproportionate overgrowth associated with heart enlargement, oedema and 
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fetal death [19]. Igf2 null mice are viable, depending on the genetic background, but have almost half 
the adult body weight [19]. 
Key questions about how IGF2-mediated growth effects are developmentally programmed and how 
IGF2 contributes to organ growth control in-vivo remain unanswered. The normal timing, location and 
duration of IGF2 supply at the organ level are likely to be crucially important. The pancreas serves as 
an interesting model for the study of these processes, as it requires tight spatial and temporal 
regulation of proliferation, differentiation and morphogenesis. Very little is known about the main 
sites of Igf2 expression and imprinting during pancreas development. Moreover, most mouse 
transgenic studies conducted so far have been directed to the beta-cells, in which Igf2 is 
overexpressed [20,21] or knocked-out [22], or focused on mice that overexpress Igf2 [23,24] or lack 
Igf1 and Igf2 constitutively [25]. Here we describe the generation of a conditional knock-out allele for 
Igf2 and perform analyses of cell-type specific deletions that target the developing pancreatic 
mesenchyme (Nkx3.2-Cre), or epithelium (Ptf1a-Cre), with the overall aim of defining the paracrine 
and autocrine roles of IGF2 in pancreatic growth. 
 
Results 
The mesenchyme-derived cells are the main source of Igf2 in the developing perinatal and postnatal 
pancreas 
We first sought to establish which major cell types within the developing mouse pancreas express Igf2 
transcripts and to determine their relative levels. To achieve this aim, we used a recombinase inducible 
YFP reporter under the control of the Rosa26 locus (Rosa26YFP-stopfl/fl) [26] and crossed this mouse 
model with transgenic strains that express Cre recombinase in the main cell types of the developing 
pancreas, i.e. Nkx3.2-Cre: mesenchyme [27]; Ptf1a-Cre: pancreatic epithelium [28]; RIP-Cre: beta-cells 
[29]. We confirmed the activity of each Cre line by performing immunofluorescence staining for YFP 
in combination with cell-type specific markers in histological sections (Fig 1A). We then performed an 
expression timeline analysis based on fluorescence activated cell sorting (FACS) of YFP-positive cells 
isolated from pancreas at various developmental stages, ranging from embryonic day 16 (E16) to 
adulthood, followed by qRT-PCR measurements of Igf2 mRNA levels (Fig 1B, S1A Fig). This analysis 
revealed that mesenchyme-derived cells express the highest levels of Igf2 mRNA when compared to 
beta-cells or non-mesenchyme cells (which is comprised of acinar, endocrine, ductal and endothelial 
cells) (Fig 1B). At E16, mesenchyme-derived cells express 380 fold more Igf2 than beta-cells and 1.5 
fold more than non-mesenchyme cells. At P14, the difference between mesenchyme and non-
mesenchyme is the greatest, with mesenchyme-derived cells expressing 700 fold more Igf2 than non-
mesenchyme cells. The levels of Igf2 in mesenchyme-derived cells remain high in the neonatal period 
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until the weaning period (at P21 levels are 3.2 fold reduced compared to E16, followed by a steep 
decline in adulthood) (Fig 1B). Interestingly, both non-mesenchyme cells and the beta-cells decrease 
their Igf2 expression levels after E16. To verify that the mesenchyme-derived cells express high levels 
of Igf2 mRNA, we next performed in situ hybridization analysis at E19, P2 and P5. Our results confirm 
that Igf2 transcripts are localized in mesenchyme-derived cells surrounding the vessels, pancreatic 
acini and ducts, with low to undetectable expression in endocrine and acinar cells (Fig 1C). 
The results presented above suggest that Igf2 is a mesenchymal-derived cell marker in the neonatal 
and post-natal period, with mostly restricted expression to these cell types compared to non-
mesenchyme. To confirm this observation, we next performed RNA-seq analyses in mesenchyme-
derived cells and non-mesenchymal cells isolated by FACS from pancreases of Rosa26YFP-stop+/fl ; 
Nkx3.2Cre/+ mice at P2. We found over four thousand differentially expressed genes (DEGs, fold change 
>1.5; FDR adjusted p value <0.05) between the mesenchyme-derived cells and non-mesenchyme cells 
in wild-type Igf2+/+ pancreases (S2A Fig, S1 Data). A number of these DEGs were validated by qRT-PCR 
in independent biological replicates (S2B Fig). Using DAVID functional annotation (see Materials and 
Methods) we identified over 20 significantly enriched GO terms (FDR adjusted p value <0.05), which 
included biological processes known to be involved in pancreatic mesenchyme function (e.g. Wnt 
signalling), early pancreas development (e.g. retinoic acid and SMAD signalling) and epithelial-
mesenchymal interactions (integrin-mediated signalling, cell adhesion, collagen catabolism) (Fig 2A). 
This analysis also highlighted unexpected pathways, such as semaphorin-plexin and insulin-like growth 
factor receptor signalling (Fig 2A). Notably, several gene members of the IGF signalling family are 
highly enriched in mesenchyme-derived cells versus non-mesenchyme (Fig 2B). Interestingly, 
imprinted genes, with known roles in growth control, make up almost one third of the top 30 genes 
most highly expressed genes in the pancreatic mesenchyme-derived cells, with Igf2 being the highest 
(Fig 2C) and one of the most enriched compared to non-mesenchyme cells (53 fold) (S2A Fig, S1 Data). 
DAVID functional annotation identified 17 GO terms enriched in non-mesenchyme cells including 
expected pathways, such as digestion and endocrine pancreas development, as well as novel 
pathways, such as peptidyl-tyrosine phosphorylation (S2C Fig, S1 Data). Contrary to mesenchyme-
derived cells, no imprinted genes are found amongst the top 30 most highly expressed genes in non-
mesenchyme cells (S2D Fig). 
The observation of high levels of expression in the mesenchyme-derived cells isolated at P2 for several 
imprinted genes, including Igf2, prompted us next to extend our analysis to earlier developmental 
time points. We analysed the recently published transcriptomes of E13.5, E15.5 and E17.5 pancreatic 
mesenchyme-derived cells [3] isolated by FACS in Rosa26YFP-stop+/fl ; Nkx3.2Cre/+ genetic crosses, as 
also used in our study. Similar to our observations at P2, the eight imprinted genes exhibit very high 
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levels of expression at all three embryonic stages (Fig 2D) and Igf2 ranks among the top 22 most highly 
expressed genes. Additionally, all gene members of the IGF signalling family identified in our analysis 
at P2 were expressed in E13.5, E15.5 and E17.5 pancreatic mesenchyme-derived cells, with ten of 
these genes reaching levels above 50 FPKM at all three developmental time points (Fig 2E). Our 
analysis further shows that at all three embryonic stages, as well as at P2, the pancreatic mesenchyme-
derived cells express not only pericyte markers, as previously published [3], but also markers of other 
cell types, including smooth muscle cells, fibroblasts and myofibroblasts (S3 Fig), and in agreement 
with the highly heterogeneous histological features that we observed at P2 (Fig 1A).   
To accurately measure the contribution of the various cell types to the overall pancreatic Igf2 levels 
in the neonatal period, we analysed cell-type specific deletions of Igf2 using floxed mice  (Igf2+/fl) that 
we generated  (S4 Fig, S5 Fig). Deletion of Igf2 from mesenchymal-derived cells reduced its total 
pancreatic levels by more than 80% (Fig 2F). Notably, mesenchyme-derived cells represent 10.3 ± 1.2% 
(n=7) of the pancreatic tissue weight at this time point, as measured by stereology. Ptf1a-Cre mediated 
deletion of Igf2 in exocrine, endocrine and ductal cells (S1B Fig) showed no discernible changes in the 
whole pancreas Igf2 mRNA, which is consistent with in situ hybridisation data shown (Fig 1C). Deletion 
of Igf2 from endothelial cells (mediated by Tek-Cre [30]) reduced Igf2 mRNA with approximately 20-
25% (Fig 2F). Altogether, these results demonstrate that the mesenchyme-derived cells are the main 
source of Igf2 in the pancreas during late gestation and early postnatal life. 
 
Mesenchyme-specific Igf2 signalling controls the growth of exocrine and endocrine pancreas 
To assess whether mesenchymal Igf2 plays a role in controlling the early growth of the pancreas, 
Igf2+/fl; Nkx3.2Cre/+ knockout mice were first analysed at the neonatal stage P2 (Fig 3A–3D). As 
expected, paternal transmission of the mutation resulted in 99% reduction of Igf2 levels at the mRNA 
level in FACS-isolated mesenchymal cells (Fig 3A), and absence of protein by immunofluorescence (Fig 
3B). Mice with deletion of the paternal Igf2 allele have normal body weight, but significantly lighter 
pancreases (69% of normal) compared to littermate controls (Fig. 3C, S6A Fig). Deletion of the 
maternal Igf2 allele has no phenotypic effects, which is consistent with findings that the maternal 
allele is transcriptionally inactive due to imprinting (S6B and 5C Fig). Importantly, Nkx3.2-Cre or Igf2 
floxed carrier mice are indistinguishable from wild-type littermates (S6A and 5B Fig). We next 
measured the number of cell nuclei in DAPI-stained paraffin sections to establish if the loss of pancreas 
weight was due to hypoplasia. We found that the number of cell nuclei was significantly reduced in 
mutants (74% of normal) compared to controls (Fig 3D). This finding suggests that mutant pancreases 
are smaller due a reduction in cell numbers, which is in agreement with the well-established role for 
IGF2 in the control of cell proliferation and survival. Stereological analysis revealed that loss of Igf2 in 
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pancreatic mesenchyme leads to decreases in acinar and beta-cell mass, in line with the overall 
pancreas weight deficit, while the mesenchymal mass remained unchanged (Fig 3D). Also consistent 
with the decrease in acinar mass, mutant pancreases contained lower amounts of lipase (11,367 ± 
5674 in n=6 mutants versus 18,343 ± 4238 in n=7 controls, p=0.035). Thus, our data reveals that the 
mesenchyme-derived IGF2 is likely to control acinar and beta-cell growth through paracrine signalling 
from the mesenchyme. 
The microRNA miR-483 is located within the intron 4 of Igf2, which is deleted alongside the Igf2 coding 
exons 4-6 upon Cre-mediated recombination. To rule out a contributory role of this microRNA to the 
phenotype, we analysed pancreases of mice carrying a miR-483 deletion [31], and found that it does 
not alter pancreas weight at P2 (S7 Fig). Furthermore, mir-483 knockout mice are normal sized, viable 
and show no evidence of impaired glucose homeostasis defects or other discernible phenotypes up to 
at least three months of age (Sekita et al. manuscript in preparation). We therefore conclude that the 
growth phenotype in the Igf2+/fl; Nkx3.2Cre/+ knockout mice can be attributed solely to IGF2 signalling 
actions.  
Next, we used a well-established mouse model of Igf2 loss-of-imprinting – the H19DMD conditional 
knockout [32] – to overexpress Igf2 specifically in the pancreatic mesenchyme (H19DMDfl/+; 
Nkx3.2+/Cre) and investigated the effects on acinar growth (Fig 4A – 4D). As expected, deletion of the 
imprinting control region (DMD) from the maternal allele resulted in increased Igf2 and decreased 
H19 RNA levels (160% and 18% of controls, respectively – Fig 4A) and increased IGF2 protein (Fig 4B), 
and was associated with a 29% increase in pancreas weight, with similar body weights between 
genotypes at P2 (Fig 4C). The acinar cell mass was increased by 34%, in line with the overall pancreas 
weight increase (Fig 4D). Beta-cell mass remained unchanged, while the mesenchymal mass increased 
by 45% (Fig 4D). We then used an Igf2 gain-of-function model that does not lead to transcriptional 
changes in Igf2 mRNA but instead results in increased IGF2 protein (Fig 4E – 4G). Accordingly, we 
deleted the IGF-type II receptor that is required for recycling IGF2 via lysosome degradation [33], 
specifically in the pancreatic mesenchyme (Igf2rfl/+; Nkx3.2+/Cre) (Fig 4E). Reduced Igf2r mRNA levels in 
the mesenchyme cells (25% of controls), was associated with a 20% increase in pancreas weight, with 
similar body weights between genotypes at P2 (Fig 4F). The acinar cell mass was also increased by 33% 
in this model (Fig 4G). Additionally, beta-cell mass was also increased, but the observed difference 
between groups (31%) did not reach statistical significance (p=0.099), while mesenchymal mass 
remained unchanged (Fig. 4G). Therefore, the two gain-of-function genetic models further 
demonstrate that IGF2 produced by the pancreatic mesenchyme-derived cells controls the growth of 
the acinar cells in a paracrine manner. 
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Mesenchyme-derived IGF2 exerts paracrine effects on pancreatic epithelium in vivo and acinar cells 
respond to exogenous IGF2 in vitro 
To investigate the molecular signatures associated with the paracrine effects exerted by the 
mesenchyme-derived IGF2, we performed genome wide-transcriptional profiling by RNA-seq in both 
fractions of Igf2+/fl; Nkx3.2Cre/+ mutants (i.e. mesenchyme-derived cells with Igf2 deleted and the 
corresponding non-mesenchyme fraction), compared to mesenchyme and non-mesenchyme cells 
isolated from controls, at the neonatal P2 stage. We found that transcriptional changes are far more 
widespread in the non-mesenchyme fraction (498 DEGs with >1.5-fold change and FDR-adjusted p 
value <0.05) (Fig 4A, S2 Data) than in Igf2-deficient mesenchyme-derived cells (151 DEGs; Fig 5A, S3 
Data). DAVID functional annotation identified 15 enriched GO terms in the non-mesenchyme fraction 
(Fig 5B, S2 Data) but only 2 in the Igf2-deficient mesenchyme fraction (namely, actin binding and 
inflammatory response, S3 Data). The top biological processes in the non-mesenchyme fraction 
enriched in genes up-regulated in mutants were related to digestion and inflammation/immune 
responses, and biological processes enriched in genes down-regulated in mutants were related to 
erythrocyte development and tRNA methylation (Fig 5B and 5C, S2 Data). These findings are in 
agreement with the stereological analyses showing that loss of Igf2 from the mesenchyme-derived 
cells impacts on the growth/function of the non-mesenchymal fraction through a paracrine effect. 
To provide additional evidence that mesenchyme-derived IGF2 acts on acinar cells in a paracrine 
manner, we next isolated primary mesenchyme-derived and acinar cells from P2 pancreases (see 
Materials and Methods) (Fig 5D–5F). Mesenchymal-derived cells secreted higher levels of IGF2 into 
the conditioned media compared to acinar cells (Fig 5G), a finding that is consistent with higher levels 
of Igf2 mRNA expression in the mesenchyme-derived cells in-vitro (Fig 5F) and in-vivo (Fig 1, Fig 2). We 
then tested the effect of exogenous IGF2 treatment on acinar cells cultured ex-vivo. Isolated acinar 
cells treated with recombinant mouse IGF2 showed increasing levels of AKT phosphorylation (S473) in 
a concentration-dependent manner (Fig 5H). Additionally, treatment of acinar cells with 50 ng/ml IGF2 
increased their cell numbers and led to a modest, but significant increase in amylase production (Fig 
5I). Altogether, the ex-vivo data shows that mesenchyme-derived cells are capable of secreting IGF2 
and that exogenous IGF2 induces intracellular signalling in acinar cells associated with increased 
enzymatic output. 
 
Post-weaning growth and glucose homeostasis analyses in Igf2 pancreas-cell type specific knockouts  
To investigate the impact of Igf2 loss-of-function from the developing mesenchyme and/or epithelium 
on post-weaning growth and glucose homeostasis, single and double Nkx3.2-Cre and Ptf1a-Cre Igf2 
knockouts were analysed (Fig 6A). The pancreas weight deficit observed in single Igf2+/fl; Nkx3.2Cre/+ 
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knockouts at P2 is maintained at weaning (S8A Fig) and is also observed at 9 weeks of age in single 
Igf2+/fl; Nkx3.2Cre/+ knockout males and females (Fig 6B). However, in contrast to the P2 time point, 
body weights are now reduced, by approximately 12% at P21 (S8B Fig), and by 5% and 10% for females 
and males, respectively, at 9 weeks of age (Fig 6C). After normalization for body weight, the mutant 
pancreases remain disproportionately smaller at both P21 and 9 weeks time points (S8A Fig, Fig 6B). 
Double Igf2+/fl; Nkx3.2Cre/+; Ptf1aCre/+ knockouts show similar pancreatic weights and body weight 
reductions to the single Igf2+/fl; Nkx3.2Cre/+ knockout (Fig 6B and 6C), thus suggesting that IGF2 
produced by the endocrine and exocrine pancreas does not play major autocrine or paracrine growth 
roles that alter pancreas size. Consistent with this hypothesis, single Igf2+/fl; Ptf1aCre/+ knockouts have 
normal pancreas sizes and body weights (Fig 6B and 6C). 
Glucose homeostasis, assessed by oral glucose tolerance tests (OGTT), was unaltered in single Igf2+/fl; 
Nkx3.2Cre/+ and Igf2+/fl; Ptf1aCre/+ knockouts, as well as in double Igf2+/fl; Nkx3.2Cre/+; Ptf1aCre/+ knockouts 
compared to Igf2+/fl controls at 8 weeks of age in both sexes (Fig 6D and 6E). We next assessed glucose 
homeostasis during pregnancy, a naturally occurring metabolic stress state. We found that 8 week old 
Igf2+/fl; Nkx3.2Cre/+ knockout females at the E15 stage of pregnancy had similar levels of glycaemia and 
insulinemia compared to age-matched pregnant Igf2+/fl littermate controls after fasting and prior to 
OGTT (time 0) (Fig 6F). However, during OGTT, pregnant Igf2+/fl; Nkx3.2Cre/+ knockout females became 
glucose intolerant compared to pregnant Igf2+/fl littermate controls (Fig 6F). Beta-cell mass, measured 
at E15, was significantly smaller in pregnant Igf2+/fl; Nkx3.2Cre/+ knockout females compared to 
pregnant Igf2+/fl littermate controls (Fig 6G). Thus, our results show that mesenchyme-specific Igf2 
deletion results in postnatal whole-body growth restriction and maternal glucose intolerance during 
pregnancy. 
 
Discussion  
This study uncovers novel roles for IGF signalling in the developmental regulation of adult pancreas 
size, with consequences for energy homeostasis and post-natal whole body-growth. We first observed 
that gene members of the IGF signalling pathway, which include IGF2 and IGF1 ligands, are highly 
enriched in the neonatal mesenchyme-derived cells compared to the non-mesenchyme fraction. 
Moreover, IGF2 is the top expressed gene in the mesenchyme-derived cells, as revealed by RNA-seq 
profiling at postnatal day 2 (P2) and one of the top 25 most highly expressed genes at E13.5, E15.5 
and E17.5. Mesenchyme-derived cells express the highest levels of Igf2 mRNA compared to all other 
pancreatic cell types from E16 to 8 weeks postnatally. At P2 we estimate, based on conditional 
deletions of Igf2 from the diverse cell types, that ~75-85% of total Igf2 in the pancreas is expressed by 
the mesenchyme-derived cells, ~20-25% by the endothelium and less than 1% is derived from the 
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epithelium. Therefore, we hypothesized that mesenchymal IGF2/IGF signalling may play previously 
unanticipated roles in pancreatic development and generated conditional specific mouse models 
mainly targeting IGF2 levels in the mesenchyme. 
We found that mesenchymal IGF2 is principally required for normal growth of the exocrine pancreas. 
Deletion of Igf2 from the mesenchyme cells from E9.5 leads to hypoplasia of the postnatal pancreas 
(~69%N at P2, ~67%N at P21 and ~79-83%N at 9 weeks of age). The acinar mass is affected the most 
and is reduced, in line with the overall loss in pancreatic weight. This finding is in agreement with the 
reports of reduced exocrine mass in mice that lack both IGF ligands (i.e. mice lacking both Igf1 and 
Igf2 in all cells of the body), or their receptors (i.e. mice constitutively lacking both Insr and Igf1r) [25]. 
However, the contribution of the individual ligands or receptors to the loss of exocrine mass has 
remained unclear, mainly because Insr or Igf1r single total knockouts result in either normal or 
increased exocrine mass, respectively, and single Igf1 or Igf2 total knockouts were not studied for 
pancreatic phenotypes. Our work now demonstrates that IGF2 is a key factor promoting acinar growth 
during development. Crucially, we have ruled out a role for IGF2 expressed in the developing 
epithelium, which includes IGF2 expressed in acinar cells, as a determinant of exocrine pancreas 
growth. Accordingly, deletion of Igf2 using Ptf1a-Cre, results in normal pancreatic growth. We 
therefore conclude that the effect of IGF2 on pancreas growth is restricted primarily to signalling from 
the mesenchyme.  
We next addressed the question of how mesenchymal IGF2 regulates pancreas size. We propose that 
this is mainly achieved through secretion of IGF2 from the mesenchyme and signalling to the 
neighbouring cells types in a paracrine manner (Fig 6H). This hypothesis is based on the following 
findings: in primary cell cultures we show that mesenchyme-derived cells secrete IGF2 into the culture 
media, and that exogenous IGF2 stimulates activation of a key signalling node, AKT, downstream of 
IGF1R and INSR in acinar cells, increasing their number and enzymatic production. In vivo, increased 
IGF2 levels specifically in the mesenchyme led to significant overgrowth of the exocrine pancreas, as 
shown in two distinct genetic models (H19DMDfl/+; Nkx3.2+/Cre, and Igf2rfl/+; Nkx3.2+/Cre). Importantly, 
deletion of Igf2 from the mesenchyme leads to a reduction in beta-cell mass (~82% N at P2 and ~84% 
N in pregnant females at E15), showing that the paracrine effects are not exclusive to the exocrine 
pancreas. We found that mesenchyme mass at postnatal day 2 was not affected by the deletion of 
mesenchymal Igf2 or overexpression of IGF2 in the mesenchymal Igf2r mutant model. These findings 
strongly support the hypothesis that the effects of the mesenchyme are mainly paracrine, thus 
suggesting that a) the pancreas growth restriction occurs independently from the loss of 
mesenchyme-derived cells; b) the function of the IGF2 producing mesenchyme-derived cells is mainly 
to act as a developmental reservoir for IGF2 paracrine signalling. The lack of mesenchymal IGF2 has 
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important physiological consequences. It is well established that the pancreas size must match the 
physiological demands of the host organism to promote nutrient digestion and absorption in the gut 
and to maintain glucose homeostasis. In this study, we report that mesenchyme Igf2-deficient mice 
have a disproportionately smaller pancreas, with a 30% size reduction at P2, which is associated with 
a reduced output of secreted acinar enzymes, such as lipase. Our data suggests that nutrient 
malabsorption due to loss of exocrine mass and/or exocrine dysfunction might be causative of the 
postnatal growth restriction, which is first observed in these mice at weaning and maintained 
throughout adulthood. Mouse models with perturbations of lipase genes such as colipase (Clps) and 
pancreatic-lipase related protein 2 (Pnliprp2) exhibit a similar body weight growth defect phenotype 
due to an inability to process fat from mother’s milk [35,36]. It has been suggested that the lipase 
deficiency can programme a “set-point” of body weight, with an inability to catch-up in body weight 
later, due to the effects of poor weight gain during the suckling period [35,36]. Interestingly, RNA-seq 
shows that mesenchyme Igf2-deficient pancreases upregulate transcription of exocrine genes 
involved in the production of digestive enzymes. We suggest that these changes represent adaptive 
responses of the small exocrine pancreas to meet the demand for digestion and absorption of 
nutrients in early postnatal life. However, this compensatory mechanism might not be sufficient to 
match the demand, and whole-body growth restriction ensues. The RNA-seq studies also showed 
increased expression of chemokines, which are normally up-regulated by pro-inflammatory stimuli 
and attract immune cells by inducing a response from the innate and adaptive immune system [37,38]. 
Whether a pre-pancreatitis state exists, linked to the premature activation of digestive enzymes in the 
interstitial space of the pancreas, and how such a state might contribute to putative nutrient 
absorption abnormalities require further investigation. We also observed that the loss of IGF2 
paracrine effects from the mesenchyme results in a modest reduction of the beta-cell mass that does 
not impact on glucose homeostasis control in young mice under a normal diet and physiological state. 
However, induced metabolic stress, as it occurs naturally during pregnancy, leads to glucose 
intolerance. We suggest that the loss of beta-cell mass in the mutant pregnant females compared to 
controls is a contributing factor for the observed glucose intolerance. Further work is required to 
understand the precise mechanisms, which includes the generation of a double knockout of Igf2 from 
the mesenchyme and the beta-cell.  It is possible that a more severe glucose homeostasis in pregnancy 
will occur when the known autocrine IGF2 actions in the beta-cell are removed [22]. 
Our findings offer novel insights into mesenchymal factors that regulate pancreas organogenesis. Wnt, 
BMP, FGF and Hedgehog signalling pathways have been implicated as early mesenchymal factors 
regulating pancreas development and growth [2,39–43], but for the majority of these studies the 
specific roles in the mesenchyme could not be assessed (it has only recently become possible to start 
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interrogating the roles that genes play in the mesenchyme with the generation of specific Cre 
recombinases). To our knowledge, this study, using a combination of loss and gain-of-function 
conditional mouse models, is the first to identify a mesenchymal-specific paracrine growth signal of 
the developing pancreas. It also reveals that IGF signalling plays previously unappreciated roles in the 
mesenchyme function and in the epithelial-mesenchymal interactions during pancreas organogenesis. 
Igf1, like Igf2, is highly enriched in the mesenchyme-derived cells compared to non-mesenchyme cells 
and paracrine release of IGF1 from fibroblasts, which derive from the primitive mesenchyme, 
stimulate acinar cell proliferation during regeneration from acute pancreatitis [44]. Interestingly, 
deletion of Igf1 from the developing epithelium also results in normal exocrine pancreas growth [45], 
similarly to the results reported here for Igf2. Our study has also highlighted a number of growth-
related imprinted genes (including Plagl1/Zac1 a master regulator of an imprinting growth network 
[46]) that are highly enriched in the mesenchyme, and raises the interesting hypothesis that genomic 
imprinting contributes significantly to mesenchymal-specific functions during pancreas development.  
Our postnatal studies provide proof of principle that lack of mesenchyme-derived IGF2 has 
physiological consequences related to whole-body growth (first observable around weaning) and 
glucose intolerance during pregnancy. It remains to be established if pregnancy-related beta-cell mass 
expansion is impaired and the extent to which other metabolic stress states, such as ageing, high fat 
diet, acute insulin resistance states, may uncover mesenchymal IGF2 effects on beta-cell function.  
Our study has a number of limitations. Although we provide evidence that mesenchymal IGF2 is a 
long-sought promotor of acinar growth, we have not established the precise timing of the actions of 
IGF2. IGF2 is well known to promote cell proliferation and survival, with the main wave of these actions 
thought to occur in the mouse between E9-E10 [47]. Therefore, it is likely that many of the 
mesenchymal IGF2 actions in promoting pancreatic growth start during the earliest stages of pancreas 
development. However, based on RNA-seq data we also observed very high levels of Igf2 expression 
at E13.5, E15.5, E17.5 and P2. Further to the well-established mitogenic roles, IGF2 has anti-apoptotic 
actions in the endocrine pancreas during the neonatal life [7,24]. Future systematic analyses based on 
pancreas stereology and measurements of cell proliferation and apoptosis are therefore required to 
fully understand if IGF2 actions occur in the early mesenchyme and/or mesenchyme-derived cells in 
later fetal and perinatal development, and the extent to which it influences the differentiation 
programmes of progenitor cells into exocrine, endocrine and mesenchyme lineages. The genetic 
models we use in this study have some limitations as well. The effects of both H19DMDfl/+; Nkx3.2+/Cre, 
and Igf2rfl/+; Nkx3.2+/Cre models are not exclusively mediated through IGF2 signalling – H19DMDfl/+; 
Nkx3.2+/Cre results in downregulation of H19 ncRNA and its associated exonic miR-675 [48,49], and 
Igf2r serves as a mannose-6-phosphate receptor in addition to acting as an IGF2 clearance 
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receptor/signalling through G proteins [50,51]. Importantly, the complete rescue of the overgrowth 
phenotypes due to deletions of maternal H19 or Igf2r alleles in an Igf2-null background [52,53] shows 
that the majority of the effects are mediated through IGF2 signalling. However, we cannot exclude 
that subtle effects caused by IGF2-independent actions, may explain some of the inconsistent 
observations regarding mesenchyme and beta-cell mass between these models (Fig 3, Fig 4).  
In summary, we report in this study that IGF2 growth actions in the pancreas are limited to the highly 
expressing mesenchyme-derived cells, and that size-determining mechanisms are programmed in 
early life by the activity of this important growth factor in a paracrine fashion, with consequences for 
post-natal physiology. In general, this work provides novel insights into how growth factors control 
pancreatic architecture and is highly relevant to pancreas pathologies. 
 
Materials and Methods 
Generation of the Igf2fl/+ mouse 
The Igf2 gene targeting vector carried a loxP site inserted 5' of exon 4 and a loxP-flanked neomycin 
resistance cassette (neoR) inserted 3' of exon 6 (S3A Fig). Details of the cloning procedures are 
available upon request. In brief, we used a 3.1-kb SalI-PacI genomic fragment (from exon 2 to intron 
3 of Igf2) as the 5’ region of homology (5’-ROH), a 5.8-kb PacI-AfeI genomic fragment that includes the 
entire Igf2 coding sequence (exons 4 to 6) as internal ROH (Int-ROH), and a 3.1-kb AfeI-BlpI genomic 
fragment (3’ of exon 6) as 3’-ROH. The Int-ROH was flanked by a 5’ loxP site and a 3’ loxP-neoR-loxP 
sequence (S3A Fig). The targeting vector was linearized at a unique ScaI site outside the area of 
homology and 50 μg linearized vector were electroporated into passage 9, E14 129ola male ES cells, 
at 250V and 950 μF. Transfected cells were plated onto 10 gelatinized 100-mm dishes pre-seeded with 
fibroblast feeder cells. After 24 h in nonselective medium, cells were incubated for 8 days with G418 
medium (200 μg/μl) to select for neomycin resistance. Resistant clones were picked at day 9 and 
expanded into 96-well plates pre-seeded with fibroblast feeder cells. We initially screened 384 G418-
resistant clones by Southern blotting analysis of genomic DNA (gDNA) digested with EcoRI and 
hybridized the blots with a unique 511 bp 5' probe (located external to 5’-ROH and obtained by PCR 
amplification using primers 5’Pr-F: 5’-AACAACGCGGTGGTAGGGAA-3’ and 5’Pr-R: 5’-
TCAGCAGAAAAAGAAGCAGGGC-3’). Two correctly targeted clones at the 5’ end were then verified by 
Southern blot  (EcoRI digested DNA) using a 590 bp 3’ probe (located external to 3’-ROH and obtained 
by PCR amplification using primers 3’Pr-F: 5’-ACAAAGCCCAAGACAACTCC-3’ and 3’Pr-R: 5’-
CTTCCACAGTTCAAGCAACC-3’) and an additional check for multiple integrations elsewhere in the 
genome using a 583 bp Internal probe (located in Igf2 exon 6 and obtained by PCR amplification with 
primers Int-F: 5’-AGAACCCAAGAAGAAAGGAAG-3’ and Int-R: 5’-AGAAAGACAGAACTAGCAGCC-3’). One 
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clone with a single integration site and correctly targeted 5’ and 3’ loxP sites was thus identified (S3A 
Fig), with the loxP sequences further verified by Sanger sequencing (data not shown). The neoR 
cassette was excised by transiently transfecting this ES cell clone with Cre recombinase (pMC-Cre 
vector), followed by two rounds of subcloning. Correctly excised clones that carry a single 3’ loxP site 
were verified by PCR screening (480 ES subclones) and gDNA digestion with SphI restriction enzyme, 
followed by Southern blot analysis using the same 583 bp Internal probe described above (S3B Fig). 
Primers used for PCR screening of in vitro neoR deletion were: F0 5’-TGACCTCAGCAATTCAAGTCC-3’; 
F1 5’-GGTAGTGGTCTTTGGCATCC-3’ and R1 5’-CAATAACTGGGGAAAAGGAGC-3’. Two independent ES 
clones were then microinjected into C57BL/6J blastocysts and transferred into (C57BL/6J X CBA/Ca)F1 
pseudo-pregnant females to generate chimeric mice. 27 chimeras were born, all males. Germline 
transmitting mice were backcrossed into the C57BL/6J genetic background for more than 10 
generations before being used as experimental animals. Paternal transmission of the Igf2 floxed allele 
did not have any impact on fetal and placental growth kinetics (S3C Fig). Homozygous Igf2fl/fl mice 
were obtained by breeding heterozygous Igf2fl/+ parents. 
 
Mouse strains 
Targeted ES cells for the miR-483 knock-out [31] were generated and provided by Dr. Haydn Prosser 
(Sanger Institute and International Knockout Mouse Consortium Project). Details on the generation of 
the miR-483 knock-out mice (depicted in S6 Fig; Sekita et al., manuscript in preparation) are available 
upon request. Rosa26YFP-stopfl/fl mice [26] were kindly provided by Dr. Martin Turner (The Babraham 
Institute, Cambridge). H19DMDfl/fl mice [32] and Igf2rfl/fl mice [54] were generously provided by Prof. 
Bass Hassan (University of Oxford). CMV-Cre mice [55] were obtained from the Babraham Institute, 
Cambridge. This Cre recombinase is expressed soon after fertilization and allows ubiquitous deletion 
of floxed alleles in all tissues, including the germline [55]. Nkx3.2-knock-in-Cre mice [27] were kindly 
provided by Dr. Warren Zimmer (Texas A&M University). Nkx3.2 expression occurs in the mesenchyme 
of the developing pancreas, stomach and gut, as well as in the forming somites, but not in the 
endoderm-derived cells of these organs. Nkx3.2 is expressed in the pancreatic mesenchyme as early 
as E9.5 and, by E12.5, its expression becomes restricted to the mesenchymal area, which will give rise 
to the splenic bud [27]. The Nkx3.2-knock-in-Cre, in which a Cre recombinase cDNA cassette and a 
PGK-NeoR cassette were inserted in frame within exon 1 of Nkx3.2 (Bapx1) gene, faithfully replicates 
endogenous Nkx3.2 expression and directs Cre activity to the foregut mesenchyme and skeletal 
somites starting at E9.5 [2,27]. We verified the pancreatic cell-type specificity of Nkx3.2-Cre expression 
using the Rosa26YFP-stopfl/fl reporter mice and demonstrated absence of recombinase activity in 
acinar cells, pancreatic endocrine cells, endothelial cells or duct cells (Fig 1A) at postnatal day P2. Tek-
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Cre transgenic mice, in which Cre expression is controlled by the endothelial-specific receptor tyrosine 
kinase Tek (Tie2) promoter/enhancer and therefore found uniformly in endothelial cells during 
embryogenesis (E7.5 onwards) and adulthood [30], were imported from the Jackson Laboratory 
(Maine, USA). Ptf1a-knock-in-Cre mice, in which the protein-coding region of Ptf1a (exon 1 and 2) was 
replaced with a Cre-cassette, express Cre in pancreatic ducts, exocrine and endocrine cells as early as 
E10.5 [28]. In newborn pups Ptf1a-Cre expression marks all acinar cells and roughly 95% of ductal and 
insulin-producing cells, as well as 75% of glucagon-producing cells [28]. RIP-Cre mice, carry a Cre 
transgene under the control of the rat Ins2 (insulin 2) promoter (RIP) that directs expression to insulin-
positive beta-cells from approximately E8.5-9 onwards [29]. Ptf1a-Cre and RIP-Cre strains were 
obtained from Central Biomedical Services (CBS Transgenic Services, University of Cambridge). All lines 
were bred into an inbred C57BL/6J line for >10 generations.  
 
Mouse crosses and genotyping 
This research has been regulated under the Animals (Scientific Procedures) Act 1986 Amendment 
Regulations 2012 following ethical review by the University of Cambridge Animal Welfare and Ethical 
Review Body (AWERB). All mouse experiments were performed under PPL No. 80/2484 (study plan 
2484/25/13) and PPL No. 70/7594 (study plan 7594/4/15). Mice were fed standard chow diet with 9% 
of kcal from fat (SDS, Essex, UK) and housed with a 12-h light/dark cycle in a temperature-controlled 
room (22°C). For timed mating, the day of detection of a vaginal plug was noted as embryonic day 1 
(E1) and the day of birth was noted as post-natal day 0 (P0). Mice were weaned at 3 weeks of age and 
ear notches were used for visual identification and to collect tissue for PCR genotyping. 
Mouse crosses used for each experiment are listed in S1 Table. Throughout the paper, Igf2+/fl 
represents genotype of offspring that inherited the floxed allele from father; Igf2fl/+ represents 
genotype of offspring that inherited the floxed allele from mother; Igf2+/+ represents genotype of 
offspring with wild-type alleles at the Igf2 locus; Nkx3.2-Cre represents genotype of offspring that are 
heterozygous Cre-carriers (Cre/+ or +/Cre); Igf2+/fl; Nkx3.2Cre/+ represents offspring with mesenchymal Igf2 
deletion on the paternal allele, having inherited the floxed allele from father and the Cre allele from 
mother; Igf2fl/+; Nkx3.2+/Cre represents offspring with mesenchymal Igf2 deletion on the maternal 
allele, having inherited the floxed allele from mother and the Cre allele from father; H19DMDfl/+; 
Nkx3.2+/Cre represents offspring with mesenchymal H19DMD deletion on the maternal allele, having 
inherited the floxed allele from mother and the Cre allele from father. All strains were genotyped by 
standard PCR using DNA extracted from ear biopsies (adult mice) or tail DNA (embryos or post-
terminal). PCR was performed using the Red Taq Ready PCR system (Sigma Aldrich) using primers 
described in S2 Table, followed by separation of PCR amplicons by agarose gel electrophoresis.  
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Southern blotting screening of ES clones 
gDNA were digested with EcoRI or SphI restriction enzymes and electrophoresed on 0.8% agarose gels 
in 1×TBE buffer, alkaline blotted onto Hybond N+ membranes (Amersham), and UV cross-linked 
(Stratalinker, Stratagene). Probes were obtained by PCR and radiolabeled (α-32P-CTP). Hybridisation 
and washing of Southern blots was performed as described [56]. Membranes were exposed overnight 
to MS film (Kodak). 
 
Northern blotting analysis of Igf2 mRNA  
Total RNA (10 µg) extracted from E19 placenta and liver samples using RNeasy midi kits (Qiagen) 
according to manufacturer’s protocol, was separated in low-percentage formaldehyde gels, blotted 
onto Nytran-plus membrane (Schleicher and Schuell), and UV cross-linked (Stratalinker, Stratagene). 
The RNA blots were hybridized with radiolabelled (α-32P-UTP) Igf2 and Gapdh cDNA probes. We 
carried out hybridization and washing of northern blots as described [57]. Transcript levels were 
quantified by PhosphorImager analysis (Molecular analyst software, Biorad). 
 
Western blotting analyses 
For Western blot analysis of IGF2, 5 µl serum samples collected at E19 were loaded into Bis-Tris gels 
(NuPAGE Novex, Life technologies) and transferred to nitrocellulose membranes (Invitrogen). 4 ng 
human recombinant IGF2 (292-G2-050, R&D Systems) was used as positive control, and the Novex 
Sharp protein ladder (Life technologies) was used as marker. The membranes were initially stained 
with Ponceau red (Invitrogen) and imaged with the Biorad GelDoc system, the intensity of bands being 
used as internal control for protein loading. The membranes were then blocked with 5% skimmed milk 
in TBS-T for 1 h at 4°C, after which were incubated overnight at 4°C with goat anti-human IGF2 
antibody (R&D systems AF-292) diluted 1: 1,000 in TBS-T containing 0.3% skimmed milk. After 4x10 
min washes with milliQ water, the blots were incubated for 1h at room temperature with the 
secondary antibody (1:2,000 rabbit anti-goat IgG coupled to HRP, SantaCruz) in TBS-T containing 3% 
skimmed milk. Blots were washed 4x10 min with milliQ water, exposed to substrate (Clarity ECL 
Western Blotting Substrate, Biorad) for 5 minutes and imaged with the Biorad GelDoc system. Bands 
were quantified using the ImageLab software (Biorad), the output values being normalized to the 
corresponding Ponceau red loading control values. 
For Western blot analysis of AKT phosphorylation, acinar cell pellets were lysed in 30µl RIPA containing 
protease and phosphatase inhibitors. Protein concentration was determined by DC assay (Biorad) and 
10µg/lane total cell lysates were electrophoresed through 4-12% Bis-Tris NuPAGE gels with MOPS 
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running buffer. Proteins were transferred to nitrocellulose by iBlotII (Invitrogen) prior to being blocked 
for an hour in 3%BSA/TBST. Primary antibody to pAKT (S473) (CST 9271), total AKT (CST 2920), or Beta-
actin (CST 4967) was incubated overnight at 4°C. Membrane was washed 5 times before detection of 
bound antibody by chemiluminescent signal associated with HRP-conjugated anti-rabbit or anti-
mouse secondary antibody.  
 
Pancreas immunostainings, imaging and stereology analysis 
Pancreases were dissected under microscope (for embryonic and early post-natal analyses), fixed in 
4% paraformaldehyde in PBS overnight, dehydrated and then embedded in paraffin. Paraffin blocks 
were cut at 5 μm thickness, sections were then deparaffinised, rehydrated, stained and mounted with 
coverslips. For all stereological analyses, in order to obtain accurate morphometric estimations 
without measuring more than once the same feature (e.g. pancreatic islands), sections spaced at 100 
μm (P2) or 200 μm (pregnant females) were stained (6–8 sections/block for P2 and 20-24 
sections/block for pregnant females). Conditions used for antigen retrieval, blocking and combinations 
of primary and secondary antibodies used for each staining are described in S3 Table. Counterstaining 
was performed with haematoxylin for light microscopy stains or DAPI for fluorescent stains.  
Light microscopy stained slides were imaged using the NanoZoomer whole slide scanner 
(Hamamatsu). Fluorescent immunostainings were imaged with a LSM510 Meta confocal laser 
scanning microscope and the ZEN 2009 software (Carl Zeiss, Germany) or scanned using an Axio whole 
slide scanner. Whole slide scans of stained sections were analysed using the Visiopharm automated 
image quantification software (Visiopharm, Denmark) or HALO AI (Indica Labs) to measure the area of 
positive cell-specific staining or to count individual nuclei. The mass of each cell-type was calculated 
using the formula: 
 
(𝑎𝑟𝑒𝑎 𝑜𝑓 𝑐𝑒𝑙𝑙-𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑠𝑡𝑎𝑖𝑛 (μm2))×(𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠 𝑤𝑒𝑖𝑔ℎ𝑡 (mg))=𝑚𝑎𝑠𝑠 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑡𝑦𝑝𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 (mg) 
                              (𝑜𝑣𝑒𝑟𝑎𝑙𝑙 𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 (μm2))  
 
mRNA in situ hybridization (ISH) for Igf2 
ISH was performed as described [58], with minor modifications. Briefly, a region of 415 bp spanning 
coding Igf2 exons 4-6 was amplified by PCR using primers: F: 5’-CACGCTTCAGTTTGTCTGTTCG-3’ and 
R: 5’-GCTGGACATCTCCGAAGAGG-3’ and cDNA from whole P2 pancreases as template. The PCR 
product was cloned into a pCR2.1-TOPO plasmid (Invitrogen) containing M13 primers and a T7 RNA 
polymerase transcription initiation site. Sense (S) and antisense (AS) RNA probes were generated and 
labelled with Digoxigenin (DIG) by in vitro reverse transcription, according to manufacturer’s 
instructions (Roche). Pancreases were dissected in cold phosphate buffered saline (PBS) and fixed 
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overnight in 4% paraformaldehyde in 0.1% diethylpyrocarbonate (DEPC)-PBS at 4°C. After rinsing in 
DEPC-PBS, tissues were dehydrated and then embedded in paraffin in RNase-free conditions. Pancreas 
sections (7 μm thick) mounted on polysine slides (VWR) were de-waxed, rehydrated in PBS, post-fixed 
in 4% paraformaldehyde for 10 minutes, treated with proteinase K (30 μg/ml) for 10 min at room 
temperature, acetylated for 10 minutes (acetic anhydride, 0.25%) and hybridized overnight at 65°C in 
a humidified chamber with DIG-labeled probes diluted in hybridization buffer (containing 200 mM 
sodium choride, 13 mM tris, 5 mM sodium phosphate monobasic, 5 mM sodium phosphate dibasic, 5 
mM EDTA, 50% formamide, 10% dextran sulfate, 1 mg/ml yeast tRNA and 1× Denhardt's [1% w/v 
bovine serum albumin, 1% w/v Ficoll, 1% w/v polyvinylpyrrolidone]). Two 65°C post-hybridization 
washes (1× SSC, 50% formamide, 0.1% tween-20) followed by two room temperature washes in 1× 
MABT (150 mM sodium chloride, 100 mM maleic acid, 0.1% tween-20, pH7.5) were followed by 30 
minutes RNAse treatment (400 mM sodium chloride, 10 mM tris pH7.5, 5 mM EDTA, 20 μg/ml RNAse 
A). Sections were blocked for 1 hour in 1×MABT, 2% blocking reagent (Roche), 20% heat inactivated 
goat serum and then incubated overnight with anti-DIG antibody (Roche; 1:2,500 dilution) at 4°C. After 
4x20 min washes in 1× MABT, slides were rinsed in 1× NTMT (100 mM NaCl, 50 mM MgCl, 100 mM 
tris pH 9.5, 0.1% tween-20) and incubated with NBT/BCIP mix in NTMT buffer, according to 
manufacturer’s instructions (Promega). Slides were counterstained with nuclear fast red (Sigma), 
dehydrated and cleared in xylene and mounted in DPX mounting medium (Sigma). Pictures were taken 
with a camera attached to a light microscope. 
 
Fluorescence-activated cell sorting (FACS) 
Mice were sacrificed by decapitation (embryos and P2 neonates) or cervical dislocation (P5 neonates 
and older). Then, pancreases were dissected and dissociated into single cells using trypsin-EDTA 
(Sigma Aldrich) at 37°C for 20 min. After one wash with ice-cold PBS, the cells were passed through 70 
μm strainers and single-cell suspensions were sorted into YFP-positive and YFP-negative fractions 
using an Aria-Fusion cell sorter (BD Bioscience). Dead cells were excluded based on forward and side 
scatter profiles and the uptake of 7AAD (7-Aminoactinomycin D dead cell stain, Life Technologies). 
Sorted YFP-positive and YFP-negative cells were pelleted by centrifugation and flash frozen in liquid 
nitrogen, then stored at -80°C until use. 
 
Total RNA and microRNA extraction (pancreas and sorted cells) 
Total RNA was extracted from whole pancreases, cells isolated by FACS or cultured cells using the 
RNEasy Mini kit (Qiagen) or the RNEasy Micro kit (Qiagen), respectively, according to manufacturer’s 
instructions, with additional removal of contaminating DNA using QIASpin DNA eliminator columns. 
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microRNA was extracted using the miRNeasy kit (Qiagen), according to manufacturer’s instructions 
with an additional step of DNaseI treatment (Qiagen). 
 
Quantitative real-time PCR (qRT-PCR) 
Concentration and integrity of total RNA was verified by NanoDrop (Thermo Scientific) and agarose 
gel electrophoresis, respectively. For RNA extracted from whole pancreases, reverse transcription was 
performed using the RevertAid RT Reverse Transcription Kit (Life technologies), according to 
manufacturer’s instructions. In the case of total RNA extracted from sorted cells, cDNA was produced 
using the QuantiTect Whole Transcriptome Kit (Qiagen) following manufacturer’s instructions. Primers 
used for qRT-PCR are listed in S4 Table. Annealing temperatures were tested by gradient PCR using 
pancreas-cDNA as a template. qRT-PCR was performed using the SYBR Green JumpStart Taq Ready 
Mix (Sigma Aldrich) on an ABI Prism 7900 system (Applied Biosystems). Gene expression levels were 
normalized to the housekeeping gene Ppia (peptidylpropyl isomerase A or cyclophilin-A), which has 
previously been established as a good housekeeping gene for pancreas gene expression studies [59] 
and is stably expressed between various developmental time points (data not shown). For microRNAs, 
reverse transcription was performed using the TaqMan Micro RNA Reverse Transcription kit (Applied 
Byosystems), according to manufacturer’s protocol. qRT-PCR was performed using TaqMan assays 
(TM: 002560 for mmu-miR-483; TM: 001232 for snoRNA202 and TM: 001234 for snoRNA234) and 
TaqMan 2x Universal PCR Master Mix (Applied Byosystems). Levels of expression were calculated 
using the 2-ΔΔCt method [60].  
 
Complementary DNA library preparation and RNA-seq analysis 
Input RNA for genome-wide transcriptome analysis was verified for concentration and quality using 
Agilent RNA Pico chips, according to manufacturer’s instructions. All RNA samples had RNA integrity 
numbers (RIN) >7.5. Total RNA (2 ng) was whole-transcriptome amplified using the Ovation RNA–seq 
System V2 (NuGEN). To prepare the RNA–seq libraries, the amplified cDNA (2 μg per sample) was 
fragmented to 200 bp using a Bioruptor Sonicator (Diagenode), and barcode ligation and end repair 
were performed using the Ovation Rapid DR Library System (NuGEN). The barcoded libraries were 
combined and loaded onto an Illumina HiSeq 2500 system for single-end 50-bp sequencing at the 
Genomics Core Facility, Cambridge Institute, CRUK. The reads were aligned onto the mouse GRCm38 
genome using TopHat 2.0.11 [61]. Gene abundance and differential expression were determined with 
Cufflinks 2.2.1 [62] and expressed in fragments per kilobase per million mapped reads (FPKM). The cut 
off for expression was set at ≥ 1 FPKM. Genes with a linear fold expression change greater than 1.5 
and a Benjamini–Hochberg false discovery rate <5% were considered differentially expressed.  
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Functional annotation and enrichment analysis 
DAVID (Database for Annotation, Visualization and Integrated Discovery; v6.8 
http://david.abcc.ncifcrf.gov/, accessed March 2017) was performed to assess whether there was 
enrichment for genes implicated in particular biological processes within the differential expressed 
gene lists identified by RNA-seq. Enriched gene ontology (GO) terms with an FDR < 0.05 were 
considered significant. These terms were then clustered semantically using REViGO (Reduce and 
Visualize GO) [63], which removes redundancy. The results obtained by REViGO were ordered 
according to log10 p values. 
 
Whole pancreas lipase content and amylase measurements 
For whole pancreas lipase measurements, frozen samples were removed from -80°C and thawed on 
ice. 100 μL TK lysis buffer with proteinase inhibitors (Calbiochem) was added to each pancreas and 
tissues were disrupted on ice with a homogenizer (Biospec Tissue Tearor). Lysates were spun at 3,000 
rpm for 15 min at 4°C and supernatants were used for analysis. Lipase levels were measured using a 
lipase activity assay (Dimension RXL, Siemens). 
For amylase measurements, cultured acinar cells were lysed in 100 μL RIPA buffer, spun at 3,000 rpm 
for 15 min at 4°C and the supernatants used for analysis. Amylase levels were measured in an 
autoanalyser (Siemens Dimension RXL) through a colorimetric reaction based on the ability of amylase 
to hydrolyse the chromogenic substrate 2-chloro-4-nitrophenol linked with maltotriose (CNPG3) into 
the coloured product 2-chloro-4-nitrophenol (CNP) plus CNPG2, maltotriose G3 and glucose. The 
absorbance increase at 405 nm is proportional to the amylase activity in the sample. Amylase levels 
were normalized to the total protein content determined by a BCA assay (Pierce BCA Protein Assay 
Kit, Thermo Fisher Scientific, 23225). 
 
Primary pancreatic acinar and mesenchymal cell isolation and culture 
Primary pancreatic cells were isolated as previously described [64] and adapted here to P2 samples. 
Briefly, pancreases from an entire P2 litter were micro-dissected under microscope and sterile 
conditions and pooled in one tube containing HBSS, 0.25 mg/ml of trypsin inhibitor and 1% Penicillin-
Streptomycin mix. After rinsing, pancreases were digested for 20-30 min at 37°C with a collagenase IA 
solution (HBSS containing 10mM HEPES, 200 U/ml of collagenase IA, and 0.25 mg/ml trypsin inhibitor). 
The digestion was stopped by placing the samples on ice and addition of FBS (fetal bovine serum) for 
a 2.5% final concentration. After additional washing steps, the cell suspension was passed through a 
100 μm cell strainer, allowing the passage of acini and mesenchymal cells, while retaining the non-
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digested fragments and larger pancreatic islets. The cells were placed in the culture media (basal 
Waymouth's media containing 2.5% FBS, 1% Penicillin-Streptomycin mix, 0.25 mg/ml trypsin inhibitor, 
and 25 ng/ml of recombinant human EGF) and plated into six-well plates pre-coated with poly-L-lysine. 
After one hour incubation at 37°C under 5% (v/v) CO2 atmosphere, the floating acini were transferred 
to a new well, while the mesenchyme cells remained attached. The cells were cultured under the 
above conditions for up to four days, with daily media changes.  
 
Measurement of IGF2 secretion by primary mesenchymal and acinar cells in vitro 
The primary mesenchymal and acinar cells were isolated and cultured as described above until 
reaching confluency.  Media (1mL) was collected 24h post-confluency and freeze-dried using a Christ 
Gamma 2-16 LSC Freeze dryer. Dry pellets were re-dissolved in 50 µl RIPA buffer and IGF2 measured 
by ELISA (Mouse IGF-II DuoSet ELISA kit, R&D Systems – DY792) using an assay adapted for the 
MesoScale Discovery electrochemiluminescence immunoassay platform (MSD), as recently described 
[65].  
 
In vitro IGF2 treatments 
To assess the impact of exogenous IGF2 on intracellular signalling via AKT, freshly isolated acinar cells 
were starved for two hours in basal Waymouth's media, without FBS and EGF. IGF2 treatments (with 
vehicle or 1 nM, 10 nM or 50 nM mouse recombinant IGF2) were performed for 10 min at 37°C under 
5% (v/v) CO2 atmosphere, then the cells were immediately placed on ice, washed two times in ice-
cold PBS, pelleted and flash-frozen on dry-ice and stored at -80°C until analysed by Western blotting.  
To assess the impact of exogenous IGF2 on amylase production by acinar cells, subconfluent acinar 
cultures (48 hours after isolation) were placed in basal Waymouth's media containing 1% Penicillin-
Streptomycin mix and 0.25 mg/ml of trypsin inhibitor. FBS was replaced with Serum Replacement  
(Sigma Aldrich S0638) that does not contain any IGF2. The treated cells received 50 ng/ml mouse 
recombinant IGF2 for 48 hours, with new media added every day. After the treatment, cells were 
harvested and dissociated into single-cell suspension using trypsin, counted with a Cedex XS Analyser 
(Roche), washed, pelleted and stored at -80°C until used for amylase measurement.  
 
Oral glucose tolerance test 
Conscious mice were used for an oral glucose tolerance test after 6 hours of fasting (from 8am to 
2pm). Blood samples (≤5 μL) were taken from the tail vein immediately before administration of 
glucose by oral gavage (20% weight for volume, 2g/kg body weight based on average body weights 
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for each experimental group) and thereafter at the time points indicated, and used for glucose 
measurements with a glucose meter (AlphaTRAK).  
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 7 software. For two groups with up to 6 
samples, statistical analysis was performed using Mann-Whitney or the Wilcoxon matched-pairs 
signed rank test. For two groups with ≥6 samples, to determine whether the data was of a Gaussian 
distribution, the Shapiro-Wilk test was first applied, followed by un-paired or paired Student’s t-tests, 
as appropriate. Where more than two groups exposed to the same treatment were analysed, 1-way 
ANOVA with Dunnett’s post-hoc or Friedman’s test with Dunn’s correction tests were used, comparing 
every mean to a control mean. OGTT data was analysed using two-way ANOVA with Sidak’s multiple 
comparison tests, using the time from administration and the genotype as factors (two genotypes) or 
by repeated measures 1-way ANOVA with Dunnett’s post hoc test for multiple comparisons against 
the controls (four genotypes). The area under the curve (AUC) was calculated by the trapezoidal 
rule and used for analyses by unpaired Student’s t tests (two genotypes) or by 1-way ANOVA with 
Dunnett’s post-hoc tests (four genotypes).   Unless stated otherwise, data is shown as average values 
and error bars represent SEM or SD. N.S. p >0.05; * p ≤0.05; ** p ≤0.01, *** p ≤0.001.  
 
Data availability 
RNA-seq data have been deposited in the Gene Expression Omnibus (GEO) under the accession 
number GSE100981. Other data and materials are available upon request from the corresponding 
author. 
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Fig 1. Developmental profiling of cell type specific Igf2 mRNA expression in mouse pancreas. 
(A) Assessment of Cre recombinase specificity using the Rosa26YFP-stopfl/fl reporter mouse line at 
postnatal day 2. Cells with a functional Cre recombinase express YFP protein (green). Nkx3.2-Cre is 
active in mesenchyme-derived cells (pericytes, smooth muscle cells, stromal cells surrounding 
pancreatic ducts and acini, fibroblasts and myofibroblasts), Ptf1a-Cre in pancreatic epithelium (acinar 
cells, pancreatic islets and ducts) and RIP-Cre in pancreatic beta-cells.  Sections were co-stained with 
insulin (INS) marker of pancreatic beta-cells; cholecystokinin (CK), marker of epithelial cells lining 
pancreatic ducts; amylase (AMY) marker of acinar cells and CD31, marker of endothelial cells. Scale 
bars are as following: 500 μm in panels i corresponding to each Cre-line; 50 μm in panels ii 
corresponding to each Cre-line;  100 μm (panel iii) and 200 μm (panels iv and v) for Nkx3.2-Cre. (B) 
Timeline of Igf2 mRNA expression measured by qRT-PCR in YFP+ or YFP– FACS isolated cells from 
offspring of Nkx3.2-Cre or RIP-Cre females mated with Rosa26YFP-stopfl/fl males (E – embryonic day; 
P – postnatal day). Highest levels of Igf2 expression are observed in the mesenchyme fraction (Nkx3.2-
Cre YFP+ cells) throughout development. Expression data is normalized to Ppia and is shown as 
average + SD (n=3–5 per time point and cell fraction). (C) Igf2 mRNA analysis by in situ hybridization 
at E19, P2 and P5 showing high levels of expression in mesenchymal cells (purple colour). AS – 
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antisense probe; S – sense probe (negative control); Ac – acinar cells; Isl – pancreatic islet; Du – 
pancreatic duct; arrows point to cells expressing high levels of Igf2 mRNA. Scale bars are as follows: 
E19 (300 μm); P2 (100 μm); P5 (30 μm for higher resolution panels ii and iii and 300 μm for lower 
resolution panels i and iv). 
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Fig 2. Perinatal pancreatic mesenchyme-derived cells are enriched in imprinted genes (including 
Igf2) and genes related to IGF signalling. 
(A) Top scoring biological processes containing genes enriched in the pancreatic mesenchyme-derived 
cells as identified by DAVID functional annotation. The dotted line in panel corresponds to a p value 
of 0.05. (B) Genes related to IGF signalling that are significantly enriched in mesenchyme-derived cells. 
Data is shown as average FPKM + SEM (n=4), ranked by levels of expression. FDR adjusted p values: * 
p<0.05, ** p<0.01 and *** p<0.001. (C) Top 30 expressed genes with highest FPKM values in 
pancreatic mesenchyme-derived cells (average FPKM + SEM in mesenchyme and non-mesenchyme 
cells with n=4 per group) at P2. Note that all 30 genes are significantly enriched in mesenchyme 
compared to non-mesenchyme (>1.5 fold, FDR adjusted p value <0.05). Asterisks indicate imprinted 
genes, of which there are 8 amongst the top 30. (D) RNA-seq data showing high levels of expression 
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in mesenchyme-derived cells (as FPKM ± SEM) during embryonic life (E13.5, E15.5 and E17.5, n=2 per 
developmental stage; data derived from [3]) of the top eight imprinted genes identified at P2 as shown 
in panel (C). (E) RNA-seq data showing high levels of expression in mesenchyme-derived cells (as FPKM 
± SEM) during embryonic life (E13.5, E15.5 and E17.5, n=2 per developmental stage; data derived from 
[3]) of genes related to IGF signalling identified at P2 as shown in panel (B). (F) Residual Igf2 mRNA 
levels after conditional Igf2 deletion in different pancreatic cell types, measured by qRT-PCR in whole 
pancreas lysates at P2 from offspring of heterozygous Cre females mated with Igf2+/fl males. Residual 
levels of Igf2 mRNA in each mutant are indicated as percentage values of controls. Data was 
normalized to Ppia and shown as individual values and averages ± SD relative to levels in control 
littermates, which were arbitrarily set to 100; (n=6-7 samples per genotype; N.S. – non-significant; * 
p<0.05; *** p<0.001 by unpaired Student’s t-test). 
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Fig 3. Impact of mesenchyme-specific deletion of Igf2 on pancreas at postnatal day 2 (P2). 
(A) Left: schematic representation of conditional Igf2 deletion from the pancreatic mesenchyme. 
Right: reduced Igf2 mRNA expression levels in FACS-isolated pancreatic mesenchyme-derived cells of 
mutant mice (Mut: Igf2+/fl ; Rosa26YFP-stop+/fl ; Nkx3.2Cre/+) compared to control littermates (C: Igf2+/+ ; 
Rosa26YFP-stop+/fl ; Nkx3.2Cre/+) measured by qRT-PCR (data normalized to Ppia and shown relative to 
levels in controls). (B) Representative immunofluorescence confocal microscopy showing 
cytoplasmatic staining (inset) for IGF2 in pancreases of control mice (Igf2+/+) and absence of signal in 
mutants (Igf2+/fl ; Nkx3.2Cre/+). Green – IGF2; blue – DAPI staining of nuclei; scale bars – 100 μm and 10 
μm for lower and higher magnification panels, respectively. (C) Pancreas weights are significantly 
reduced in mutants with conditional deletion of Igf2 in the mesenchyme (Mut: Igf2+/fl ; Rosa26YFP-
stop+/fl ; Nkx3.2Cre/+), compared to littermate controls (C: Igf2+/+ ; Rosa26YFP-stop+/fl). Body weights are 
similar between genotypes. (D) Stereological measurements show significant reductions in the total 
number of nuclei/section, acinar mass and beta-cell mass (shown as %) in mutants (Mut: Igf2+/fl ; 
Rosa26YFP-stop+/fl ; Nkx3.2Cre/+), compared to littermate controls (C: Igf2+/+ ; Rosa26YFP-stop+/fl ; 
Nkx3.2Cre/+), but not for the mesenchyme mass. For all graphs, data is shown as individual values and 
averages ± SD; N.S. – non-significant, * p<0.05, ** p<0.01 and *** p<0.001 by unpaired Student’s t 
tests [panels (A), (C), and (D)]. 
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Fig 4. Impact of mesenchyme-specific Igf2 gain-of-function on pancreas at postnatal day 2 (P2). 
(A) Left: schematic representation of conditional Igf2 overexpression in pancreatic mesenchyme. 
Right: increased Igf2 mRNA expression and reduced H19 RNA levels in whole pancreases of mutant 
mice (Mut: H19DMDfl/+ ; Rosa26YFP-stopfl/+ ; Nkx3.2+/Cre) compared to control littermates (C: 
H19DMD+/+ ; Rosa26YFP-stopfl/+) measured by qRT-PCR (normalized to Ppia and shown relative to 
levels in controls). (B) Left: western blot analysis of Prepro-IGF2 and Pro-IGF2 in the two models of 
Igf2 loss-of-function and Igf2 gain-of-function. Right: quantification graph for Pro-IGF2/SOD1 ratios 
only. (C) Pancreas weights are significantly increased in mutants with conditional Igf2 overexpression 
in the mesenchyme (Mut: H19DMDfl/+ ; Rosa26YFP-stopfl/+ ; Nkx3.2+/Cre), compared to littermate 
controls (C: H19DMD+/+ ; Rosa26YFP-stopfl/+). Body weights are similar between genotypes. (D) 
Stereological measurements show a significant increase in acinar mass and mesenchyme mass, but 
not in beta-cell mass in mutants with conditional Igf2 overexpression in the mesenchyme (Mut: 
H19DMDfl/+ ; Rosa26YFP-stopfl/+ ; Nkx3.2+/Cre), compared to littermate controls (C: H19DMD+/+ ; 
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Rosa26YFP-stopfl/+ ; Nkx3.2+/Cre). (E) Left: schematic representation of conditional Igf2r deletion in 
pancreatic mesenchyme. Right: reduced Igf2r mRNA levels in whole pancreases of mutant mice (Mut: 
Igf2rfl/+ ; Rosa26YFP-stopfl/+ ; Nkx3.2+/Cre) compared to control littermates (C: Igf2r+/+ ; Rosa26YFP-
stopfl/+) measured by qRT-PCR. Data was normalized to Ppia and is shown relative to levels in controls 
(arbitrarily set to 1). (F) Pancreas weights are significantly increased in mutants with conditional Igf2r 
deletion in the mesenchyme (Mut: Igf2rfl/+ ; Rosa26YFP-stopfl/+ ; Nkx3.2+/Cre), compared to littermate 
controls (C: Igf2r+/+ ; Rosa26YFP-stopfl/+). Body weights are similar between genotypes. (G) 
Stereological measurements show a significant increase in acinar mass and a trend for increased beta-
cell mass (P=0.099), but similar mesenchymal mass in mutants with conditional Igf2r deletion in the 
mesenchyme (C: Igf2r+/+ ; Rosa26YFP-stopfl/+; Mut: Igf2rfl/+ ; Rosa26YFP-stopfl/+ ; Nkx3.2+/Cre). For all 
graphs, data is shown as individual values and averages ± SD; N.S. – non-significant, * p<0.05, ** 
p<0.01 and *** p<0.001 by unpaired Student’s t tests [panels (A), (C), (D), (E), (F) and (G)] or 1-way 
ANOVA followed by Dunnett’s post hoc test for multiple comparisons against the Igf2+/+ ; Nkx3.2Cre/+ 
controls [panel (B)]. 
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Fig 5. Loss of Igf2 in pancreatic mesenchyme causes significant transcriptional changes in non-
mesenchymal cells in vivo and acinar cells respond functionally to exogenous IGF2 ex vivo. 
(A) Volcano plot representing all expressed transcripts (by RNA-seq) in Igf2-deficient pancreatic 
mesenchyme (left) and in corresponding non-mesenchyme cell fraction (right), compared to 
mesenchyme and non-mesenchyme controls, respectively. Expression changes detected in the right 
panel thus reflect changes caused by lack of Igf2 from the mesenchyme on neighbouring non-
mesenchymal cells. Blue and red dots depict statistically significant down-regulated and up-regulated 
genes (fold change >1.5 fold FDR adjusted p value <0.05), respectively, and black dots show genes that 
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are not statistically different; (n=3 mutants and n=4 controls per cellular fraction). There are more 
differentially expressed genes (DEGs) in the non-mesenchyme fraction (216 down-regulated and 282 
up-regulated genes) than in the mesenchyme (109 down-regulated and 42 up-regulated genes) (all 
genes are listed in S2 and S3 Data). (B) Biological processes enriched in down-regulated (blue) and 
upregulated (red) genes between non-mesenchyme of Igf2+/fl; Nkx3.2Cre/+ mutants and Igf2+/+; 
Nkx3.2Cre/+ controls as identified by DAVID (for a complete list of biological processes, see S2 Data). 
ACEA – activation of cysteine-type endopeptidase activity. The horizontal axis shows -Log10 of p value; 
the dotted line corresponds to a FDR-corrected p value of 0.05. (C) DEGs in non-mesenchymal mutant 
cells compared to control cells, grouped according to selected enriched biological processes shown in 
(B). Data is shown as average FPKM + SEM, ranked by levels of expression (the inset depicts lower 
expressed genes related to “digestion”, with a different scale bar). FDR adjusted p values: * p<0.05, 
** p<0.01 and *** p<0.001. (D) Primary mesenchyme-derived cells (Mes) and acinar cells (Ac) isolated 
from P2 pancreases. Representative images are shown after one and four days in culture. (E) Staining 
for the acinar marker amylase (AMY, red) in primary mesenchyme-derived (Mes) and acinar (Ac) cells 
after four days in culture. Blue – DAPI, staining of nuclei; scale bars – 100 μm. (F) mRNA expression 
levels of acinar (Try, Amy2) and mesenchymal (Sema5b, Sfrp1, Igf2) signature genes measured by qRT-
PCR after four days of culture, showing high purity of the primary cell cultures. (G) Measurement of 
IGF2 protein secreted by mesenchymal or acinar cells in the culture media. Dotted line corresponds 
to background readings in media only. (H) Levels of AKT phosphorylation (pAKT-S473) after 10 minutes 
treatment of freshly isolated acinar cells with increasing doses of IGF2 (0nM to 50nM) by western 
blotting, and quantified against total AKT levels (n=4 independent biological replicates). (I) Effect of 
IGF2 treatment [IGF2 (+): 50 ng IGF2/ml] of primary acinar cells on total cell number (left panel) 
compared to non-treated cells [(IGF2 (-)], and amylase production normalized per protein content 
(right panel). For all graphs shown in panels (F) – (I), data is shown as individual values and/or averages, 
error bars represent SD. * p<0.05, ** p<0.01, *** p<0.001 by Mann-Whitney tests [(F), (G)], 
Friedman’s test with Dunn’s correction for multiple comparisons (H) and the Wilcoxon matched-pairs 
signed rank test (I). 
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Fig 6. Growth and glucose homeostasis regulation in pancreas-cell type specific Igf2 knockout mice 
in adulthood. 
(A) Schematic representation of the mating strategy used to generate control mice (black) and 
littermates with Igf2 deletion in the pancreatic mesenchyme only (purple), mesenchyme plus 
epithelium (orange) or epithelium only (blue). (B) Pancreas weights at 9 weeks of age for males (n=20-
22 per genotype) and females (n=11-15 per genotype). Significant reductions in weight (shown as %) 
are only observed in mice that carry a deletion of Igf2 in the mesenchyme; values within brackets 
show % reduction after normalization to body weight; *** p<0.001 by 1-way ANOVA with Dunnett’s 
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multiple comparisons tests against controls. (C) Growth kinetics from weaning to 9 weeks of age for 
males (n=20-22 per genotype) and females (n=11-15 per genotype). ** p<0.01 and *** p<0.001 by 
repeated measures 1-way ANOVA with Dunnett’s post hoc test for multiple comparisons against the 
controls. Oral glucose tolerance tests performed in 8-week old males (D) and females (E) fed chow 
diet, after six hours of fasting. (F) First two graphs on left side: baseline glucose and insulin levels 
measured after six hours fasting (at T0), before the start of the oral glucose tolerance test (OGTT) 
(n=16 Igf2+/fl controls and n=15 Igf2+/fl; Nkx3.2Cre/+mutants). Third graph: OGTTs performed in 8-week 
old Igf2 mesenchyme-specific deficient pregnant females (E15 of gestation). Fourth graph: area under 
curve (AUC). (G) Left: insulin staining (brown) and hematoxylin counterstaining (blue) in sections 
collected from E15 pregnant females (scale bars are 250 µm). Right: beta-cell mass quantification 
(n=10 Igf2+/fl controls and n=9 Igf2+/fl; Nkx3.2Cre/+mutants). For (D), (E) and (F, third graph) changes in 
blood glucose concentrations (y-axis) from basal pre-treatment values with time (x-axis) after glucose 
administration are shown. The graphs on the right side indicate AUC, calculated using the trapezoid 
rule. For all panels, data is shown as individual values or average values ± SD; N.S. – non-significant. * 
p<0.05 and *** p<0.001 by unpaired Student’s t tests [panel (G) right side and panel (H) right side], or 
two-way ANOVA with Sidak’s multiple comparison tests [panels (B), (C), (D), (E) and (G) left side]. (H) 
Suggested model of mesenchymal IGF2 actions in the developing pancreas: IGF2 expression is high 
(IGF2high) in the mesenchymal cells (Mes) of the pancreas and low (IGF2low) in other pancreatic cell 
types (Ac – acinar cells, Isl – pancreatic islet cells, Du – pancreatic duct cells). IGF2 produced by the 
mesenchymal cells exerts paracrine effects (green arrows) on pancreatic acinar cells and pancreatic 
islets. 
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S1 Fig. Assessment of efficiency of pancreas-expressing Cre lines using the Rosa26YFP-stopfl/fl 
reporter mouse, at postnatal day 2 (P2). 
(A) Strategy used for sorting YFP+ and YFP- cells by FACS. Top left panel: side scatter area (SSC-
A) versus forward scatter area (FSC-A) plotting was used to identify cells of interest (gated) 
based on granularity and size, respectively. Top right panel: forward scatter width (FSC-W) 
versus forward scatter area (FSC-A) was then used to exclude cell doublets. Bottom panels: 
gates used to discriminate YFP+ (green and blue rectangles)  versus YFP- cells (red rectangle), 
after exclusion of dead cells (positive for 7-Aminoactinomycin D [7-AAD]) in cells isolated from 
pancreases of two crosses: Rosa26YFP-stop+/fl ; Nkx3.2Cre/+ that activates YFP in the 
mesenchyme-derived cells (bottom left panel) and Rosa26YFP-stop+/fl; RIPCre/+ that activates 
YFP in the pancreatic beta-cells (bottom right panel). (B) Igf2 mRNA expression measured by qRT-
PCR in YFP+ cells collected from offspring with the genotypes indicated. Expression data was 
normalized to Ppia and shown as averages + SEM relative to levels measured in control (C) littermates, 
arbitrarily set to 1.  Percentage values indicate the level of Igf2 mRNA reduction relative to controls 
(n=6 samples/genotype; ** p<0.01 by Mann-Whitney tests).  
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S2 Fig. Gene expression patterns of pancreatic mesenchyme-derived cells and non-mesenchyme 
cells identified by RNA-seq at postnatal day 2 (P2). 
(A) Volcano plot representing all expressed transcripts in pancreatic mesenchyme and non-
mesenchyme cells (purified by FACS). For every transcript, the Log2 fold change between mesenchyme 
and non-mesenchyme cells was plotted against the -Log10 p value (FDR adjusted). Genes significantly 
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enriched, with a fold change >1.5 and FDR adjusted p value <0.05, in mesenchyme are depicted as 
blue dots (n=1,902 genes), in non-mesenchyme as red dots (n=2,212), and those not significantly 
enriched in either cell fraction are depicted as black dots (all genes are listed in S1 Data). Selected 
genes of interest, such as known mesenchyme-expressed genes, signature genes for the various non-
mesenchyme cell-types and imprinted genes are grouped by colour. (B) Biological validation by qRT-
PCR of DEGs between mesenchyme-derived cell and non-mesenchyme cells, identified by RNA-seq 
(n=5-6 samples per group). Expression levels were normalized to Ppia. Data is shown are average 
values; error bars represent SEM; ** p<0.01 by Mann-Whitney tests. (C) Top scoring biological 
processes containing genes enriched in the pancreatic non-mesenchyme cells as identified by DAVID 
functional annotation. The dotted line in panel corresponds to a p value of 0.05. (D) Top 30 expressed 
genes with highest FPKM values in pancreatic non-mesenchyme cells (average FPKM + SEM in 
mesenchyme and non-mesenchyme cells with n=4 per group) at P2. Note that all 30 genes are 
significantly enriched in non-mesenchyme compared to mesenchyme-derived cells (>1.5 fold, FDR 
adjusted p value <0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
 
S3 Fig. Expression of marker genes in mesenchyme-derived cells by RNA-seq. 
(A) Mesenchyme-derived cells exhibit high expression levels for known markers of pericytes, smooth 
muscle cells, fibroblasts and myofibroblasts. Expression levels (shown as FPKM + SEM) were calculated 
by analysing the RNA-seq data obtained in E13.5, E15.5 and E17.5 mesenchyme-derived cells (n=2 for 
each developmental time point) by Harari N et al. [3]. (B) Expression levels in P2 mesenchyme-derived 
cells for the same markers genes shown in panel (A) (n=4; data shown as FPKM + SEM).  
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S4 Fig. Generation of Igf2 conditional knockout mice. 
(see also Materials and Methods for further details). (A) Targeting strategy to generate an Igf2 allele 
with coding exons 4 to 6 flanked by loxP sites (not drawn to scale). Blue boxes – exons; P0-P3 – 
alternative promoters; green triangles – loxP sites; neo – neomycin cassette; WT – wild-type; T – 
targeting (construct); E – EcoRI restriction sites; 5’, Int, 3’: location of 5’, internal and 3’ Southern 
blotting probes, respectively (B) Southern blot confirmation of homologous recombination between 
targeting vector and endogenous Igf2 sequences in genomic ES cell DNA, digested with EcoRI and 
hybridized with 5’, Int or 3’ probes. Diagnostic molecular weights (kb) are indicated in each panel. T 
and WT – targeted and wild-type clones, respectively. (C) Screening strategy for loxP recombination 
events (not drawn to scale). Correctly targeted ES clones (as shown in (B)) that are transiently exposed 
to Cre recombinase in vitro will undergo three possible independent recombination events involving 
the loxP sites, which can be discriminated by PCR and Southern blotting. F0, F1, R1 – PCR screening 
primers; S – SphI restriction sites; Int – Internal Southern probe (D) Five 96-well plates containing 
targeted ES cells transfected with Cre recombinase were screened by F1+R1 primer PCR (panel i) or 
F0+R1 primer PCR (panel ii). F1+R1 PCR products of 221 bp, 1.4 kb and 328 bp are diagnostic of the 
wild-type allele, neomycin cassette, and neomycin cassette deletion, respectively (panel i).  F0+R1 PCR 
products of 520 bp are diagnostic of a deletion that includes the neomycin cassette and exon4-6 region 
(in panel (ii)). Since all clones that had deletion of the neomycin cassette (i.e. 328 bp) also had cells 
45 
 
with deletion of exon4-6 region (520 bp), the clone indicated with a star in panel (i) was subsequently 
subcloned for selection of cells with neomycin cassette excision events only. (E) Representative ES 
subclones (starred) with deletion of the neomycin cassette only (i.e. 328 bp in panel (i) but absence of 
520 bp PCR product in panel ii). (F) Southern blot confirmation of deletion of the neomycin cassette 
in ES subclones identified in (E). DNA was digested with SphI and hybridized with the internal probe: 
6.4 kb – wild-type allele (WT); 3.9 kb – floxed allele (fl), resulting from Cre-induced deletion of the 
neomycin cassette. (G) PCR genotyping of Igf2+/fl mice was performed using primers F and RW flanking 
the 5’ loxP site (primer sequences are shown in Supplementary Table 2). A representative example of 
tail DNA PCR is shown for mice carrying one floxed Igf2 allele (lane 1) wild-type littermate (lane 2); 
lane 3 – no template PCR control; lane 4 – 100 bp DNA ladder. (H) Carriers of an Igf2 floxed allele that 
was inherited paternally show identical embryonic and placental weights as littermate controls (E12: 
n=8 wild-type and n=3 floxed; E14: n=16 wild-type and n=7 floxed; E16 n=12 wild-type and n=10 
floxed; E19: n=29 wild-type and n=24 floxed). Data is shown as average weight; error bars represent 
standard deviation (SD). 
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S5 Fig. CMV-Cre-mediated deletion of the Igf2 floxed allele in vivo. 
(A) PCR strategy to identify deletion events at DNA level. PCR products obtained in a tri-primer 
(F+RW+RD) PCR are diagnostic of the wild-type allele (WT: 324bp), floxed allele (fl: 449 bp) and deleted 
allele (Del: 384bp). Representative tail DNA PCR examples are shown in (B) for Igf2+/fl mice that carry 
floxed and wild-type alleles (lane 1), Igf2+/fl ; CMVCre/+ mice carrying deleted and wild-type alleles (lane 
2), Igf2+/+ control littermates with wild-type alleles only. (C) to (G) CMV-Cre mediated deletion of the 
Igf2 floxed allele in vivo. Heterozygous floxed Igf2 males were mated with females homozygous for 
CMV-Cre (active in all cells of embryos and placentae), and offspring analysed for levels of Igf2 deletion 
by northern blotting (C), Western blotting (D) and (E), and growth curves from E14 to E19 of gestation 
((F) and (F)). (C) Northern blot analysis of Igf2 mRNA levels, showing wild-type levels of expression in 
controls (Igf2+/+; CMVCre/+) in both placenta (PL) and liver (LV) at E19, and absence of all Igf2 transcripts 
upon CMV-Cre mediated deletion of the paternally inherited floxed allele (Igf2+/fl; CMVCre/+). Gapdh – 
internal control for RNA loading. (D) Western blotting analysis of the mature form of IGF2 in serum 
samples collected from E19 controls (C: Igf2+/+; CMVCre/+) and mutant (KO: Igf2+/fl; CMVCre/+) embryos. 
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Normalisation of IGF2 expression across samples was performed against Ponceau-stained protein 
band (arrow), and the relative quantification of IGF2 levels for the two genotypes is shown in (E). Data 
is shown as average values; error bars represent SEM; ** p<0.01 by Mann-Whitney test. (F) and (G) 
Mice with a CMV-Cre mediated deletion of the paternally inherited Igf2 floxed allele (Igf2+/fl; CMVCre/+) 
show a similar embryonic (F) and placenta (G) growth phenotype to Igf2 null mice, i.e. ~ half of the 
weight of littermate controls (Igf2+/+; CMVCre/+) at the end of gestation (E14: n= 3 litters; E16: n=9 
litters; E19: n=4 litters). Data is shown as average values; error bars represent SD; * p<0.05; ** p<0.01; 
*** p<0.001 using paired student t tests. 
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S6 Fig. Inheritance of Nkx3.2-Cre or Igf2 floxed alleles, or deletion of maternal Igf2 allele do not 
affect total body or pancreas weights at postnatal day 2 (P2).  
(A) Body and pancreas weights in offspring obtained from a cross between heterozygous Nkx3.2-Cre 
females and heterozygous Igf2 floxed males. (B) Body and pancreas weights in offspring obtained from 
a cross between heterozygous Igf2 floxed females and heterozygous Nkx3.2-Cre males. (C) Igf2 mRNA 
levels measured by qRT-PCR in pancreases with a deletion of the maternal Igf2 allele in the 
mesenchyme. Data is normalized to Ppia and shown relative to average Igf2 levels in controls (C – 
Igf2+/+ ; Rosa26YFP-stopfl/+), set to 1. Data is shown as averages or individual values; error bars 
represent SEM. Numbers shown indicate numbers of animals for each genotype. Data was analysed 
using one-way ANOVA with Dunnett’s multiple comparison test against the control group for panels 
(A) and (B) and by unpaired Student’s t test in panel (C); N.S. – non-significant; *** p<0.001. 
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S7 Fig. Paternally inherited miR-483 deletion does not lead to reduction in pancreas size. 
(A) Gene targeting strategy to delete the intronic Igf2 miR-483. In brief, a targeting vector was used 
to replace the miR-483 sequence in intron 4 of the Igf2 gene with a PGKPuroΔtk selection cassette in 
ES cells. Removal of the selection marker was achieved by Cre-recombination between loxP sites. 
Germline transmitting miR-483 KO chimeric mice were generated by ES cell injection into blastocysts 
(Sekita, Prosser, Zvetkova et al., manuscript in preparation).  (WT – wild-type allele, T – targeted allele, 
KO – knock-out allele, P0 – P3 are alternative Igf2 promoters, Ex4 – Ex6 are the Igf2 coding exons, F 
and R indicate the position of the forward and reverse primers used for PCR genotyping). (B) miR-483 
and Igf2 expression levels measured by qRT-PCR in postnatal day 2 (P2) whole pancreas from offspring 
of heterozygous miR-483 KO males mated with wild-type females and shown relative (%) to littermate 
controls (C – miR-483+/+) set to 1. Expression data was normalized to snoR-202 and snoR-234 (for miR-
483) and to Ppia (for Igf2) and is shown as average + SEM (n=10 C and n=10 KO). N.S. – non-significant; 
*** p<0.001 by unpaired Student’s t test. (C) Total body weights and pancreas weights. Data is shown 
as averages or individual values (n=33 C and n=24 KO); error bars represent SEM; N.S. – non-significant 
differences by two-way ANOVA using genotype and litter as factors. 
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S8 Fig. Deletion of paternal Igf2 in pancreatic mesenchyme leads to reduced body and pancreas 
weights at weaning (P21). 
(A) Total pancreas weights and (B) body weights in offspring obtained from a cross between 
heterozygous Nkx3.2-Cre females and Igf2 floxed males. The value within brackets in (A) shows % 
pancreas weight reduction after normalization to body weight. Data is shown as individual values or 
averages; error bars represent SEM. Numbers of mice for each genotype are shown. Data was 
analysed using one-way ANOVA with Dunnett’s multiple comparison tests against the control group 
(C – Igf2+/+ ; Rosa26YFP-stop+/fl); N.S. – non-significant; * p<0.05; *** p<0.001. 
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S1 Data. List of genes significantly enriched (fold change >1.5; FDR adjusted p value <0.05) in 
mesenchyme and non-mesenchyme pancreatic cells at P2 in wild-type mice (Igf2+/+; Rosa26YFP-
stop+/fl; Nkx3.2Cre/+) and associated functional pathway analyses (DAVID). 
 
S2 Data. List of DEGs (fold change >1.5; FDR adjusted p value <0.05) in non-mesenchymal cells 
between Igf2+/fl; Rosa26YFP-stop+/fl; Nkx3.2Cre/+ knockouts and Igf2+/+; Rosa26YFP-stop+/fl; Nkx3.2Cre/+ 
controls at P2, and associated functional pathway analyses (DAVID). 
 
S3 Data. List of DEGs (fold change >1.5; FDR adjusted p value <0.05) in mesenchyme-derived cells 
between Igf2+/fl; Rosa26YFP-stop+/fl; Nkx3.2Cre/+ knockouts and Igf2+/+; Rosa26YFP-stop+/fl; Nkx3.2Cre/+ 
controls at P2, and associated functional pathway analyses (DAVID). 
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S1 Table. Mouse strains and crosses. 
 
Paternal 
genotype 
Maternal 
genotype 
Offspring/embryo genotypes Related to Figure 
Igf2+/+ Igf2+/+ Igf2+/+ Fig 1C 
Fig 4D–I 
 
Igf2+/fl  
 
Igf2+/+ 
Igf2+/fl S3 Fig 
Igf2+/+  
 
Igf2+/fl 
 
CMVCre/Cre 
Igf2+/fl; CMVCre/+ S4 Fig 
Igf2+/+; CMVCre/+ 
 
Igf2+/fl;  
Rosa26YFP-
stopfl/fl 
 
Nkx3.2+/Cre 
Igf2+/fl; Rosa26YFP-stop+/fl; Nkx3.2Cre/+ Fig 2F 
Fig 3A–3D 
Fig 4A–4C, Fig 5F 
S5A Fig, S7 Fig 
Igf2+/+; Rosa26YFP-stop+/fl; Nkx3.2Cre/+ 
Igf2+/fl; Rosa26YFP-stop+/fl 
Igf2+/+; Rosa26YFP-stop+/fl 
 
Nkx3.2+/Cre 
 
Igf2+/fl 
Rosa26YFP-
stopfl/fl 
Igf2fl/+; Rosa26YFP-stopfl/+; Nkx3.2+/Cre S5B and S5C Fig 
Igf2+/+; Rosa26YFP-stopfl/+; Nkx3.2+/Cre 
Igf2fl/+; Rosa26YFP-stopfl/+ 
Igf2+/+; Rosa26YFP-stopfl/+ 
Rosa26YFP-
stopfl/fl 
Nkx3.2+/Cre Rosa26YFP-stop+/fl; Nkx3.2Cre/+ Fig 1A, 1B 
Fig 2A–2C 
S1A Fig 
S2A, S2B, S2D Fig 
Rosa26YFP-stop+/fl 
 
Nkx3.2+/Cre 
 
H19DMDfl/+; 
Rosa26YFP-
stopfl/fl 
H19DMDfl/+; Rosa26YFP-stopfl/+; Nkx3.2+/Cre  
 
Fig 3E–3H 
 
H19DMD+/+; Rosa26YFP-stopfl/+; Nkx3.2+/Cre 
H19DMDfl/+; Rosa26YFP-stopfl/+ 
H19DMD+/+; Rosa26YFP-stopfl/+ 
 
Nkx3.2+/Cre 
 
Igf2rfl/+; 
Rosa26YFP-
stopfl/fl 
Igf2rfl/+; Rosa26YFP-stopfl/+; Nkx3.2+/Cre  
 
Fig 3I, 3J 
Igf2r+/+; Rosa26YFP-stopfl/+; Nkx3.2+/Cre 
Igf2rfl/+; Rosa26YFP-stopfl/+ 
Igf2r+/+; Rosa26YFP-stopfl/+ 
Rosa26YFP-
stopfl/fl 
RIPCre/Cre Rosa26YFP-stop+/fl; RIPCre/+ Fig 1A and 1B 
S1A Fig 
Igf2fl/fl 
Rosa26YFP-
stopfl/fl 
Nkx3.2+/Cre; 
Ptf1a+/Cre 
Igf2+/fl; Rosa26YFP-stop+/fl; Nkx3.2Cre/+; 
Ptf1aCre/+ 
Fig 2F 
Fig 5B–E 
 Igf2+/fl; Rosa26YFP-stop+/fl; Nkx3.2Cre/+ 
Igf2+/fl; Rosa26YFP-stop+/fl; Ptf1aCre/+ 
Igf2+/fl; Rosa26YFP-stop+/fl 
Igf2fl/fl 
Rosa26YFP-
stopfl/fl 
Tek+/Cre Igf2+/fl; TekCre/+ Fig 2F 
Igf2+/fl 
Rosa26YFP-
stopfl/fl 
Ptf1a+/Cre Rosa26YFP-stop+/fl Fig 1A 
Rosa26YFP-stop+/fl; Ptf1aCre/+ 
Igf2+/fl  
Rosa26YFP-
stopfl/fl 
Ptf1a+/Cre Igf2+/fl; Rosa26YFP-stop+/fl; Ptf1aCre/+ S1B Fig 
Igf2+/fl; Rosa26YFP-stop+/fl 
Igf2+/+; Rosa26YFP-stop+/fl; Ptf1aCre/+ 
Igf2+/+; Rosa26YFP-stop+/fl 
miR-483+/ko miR-483+/+ miR-483+/ko S6 Fig 
miR-483+/+ 
+ wild-type allele; fl – floxed allele; ko – knockout 
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S2 Table. Primers used for genotyping by PCR. 
 
Strain Primer Sequence (5’ to 3’) Primer Sequence (5’ to 3’) Amplicon 
(bp) 
Igf2+/fl F TTACAGTTCAAAGC
CACCACG 
RW 
RD 
GCCAAAGAGATGAGAAG
CACC  
GCCAAACACAGTAAAAA
GAAATGC  
WT: 324  
fl: 449 
del: 384 
H19DMDfl/+ F CAGGCCTGTCCTCA
CCTGAAC 
R GCCAGCTTGCCTTGGCA
ACCCCTT 
WT: 387  
fl: 520 
Igf2rfl/+ F CCTTCCCTCCAGGC
CGTTAC 
R GGTGAGGTCTCCATCTG
AGTACC 
WT: 225 
fl: 259 
miR-483+/ko F TACCTGCCTGTGAA
CTGCTCTG 
R ATCTGGTGCCTCCTGTCT
GGTA 
WT: 440 
KO: 457 
Nkx3.2-Cre F CCAGGCGATCCTCA
ACAAGAAGAGGG 
R-Cre 
 
R-WT 
CTCGTTCTCTTCGCTCAG
GGCTGAG 
GCCGCATAACCAGTGAA
ACAGCATTGC 
Cre: 420 
WT: 264 
Ptf1a-Cre F ACCTTTGCCTTCCCC
AAC 
R-WT 
R-Cre 
TGGTGGCTGAGGAACTC
TAC 
TGAGTGAACGAACCTGG
TCG 
WT: 286 
Cre: 590 
RIP-Cre F-WT 
 
F-Cre 
ATGTCTCCAATCCTT
GAACACTG 
CGAGTGATGAGGTT
CGCAAG 
R-WT 
R-Cre 
GCAGTGGGAGAAATCAG
AACC 
TGAGTGAACGAACCTGG
TCG 
WT: 254 
Cre: 390 
Rosa26YFP-
stop+/fl 
F TGTTATCAGTAAGG
GAGCT 
R-WT 
R-fl 
CACACCAGGTTAGCCTTT
A 
AAGACCGCGAAGAGTTT
GT 
WT: 239 
fl: 301 
Tek-Cre F TGTAAACAAGAGC
GAGTGGA 
R-WT 
R-Cre 
AGAGAATGGCGAGAAG
TCAC 
TGAGTGAACGAACCTGG
TCG 
WT: 240 
Cre: 610 
Sry F-WT 
 
F-M 
ATGTCTCCAATCCTT
GAACACTG 
CCCAGCATGCAAAA
TACAGA 
R-WT 
R-M 
GCAGTGGGAGAAATCAG
AACC 
TCAACAGGCTGCCAATA
AAA 
WT: 254 
M: 350 
CMV-Cre F-WT 
F-Cre 
ATGTCTCCAATCCTT
GAACACTG 
R-WT 
R-Cre 
GCAGTGGGAGAAATCAG
AACC 
 
WT: 254 
Cre:  
+ wild-type allele; fl – floxed allele; ko – knockout 
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S3 Table. Conditions used for pancreas immunostaining. 
 
Staining Antigen retrieval Blocking Primary antibody Secondary antibody 
Amylase Autoclaving for 15 
min at 121°C in 
citric acid buffer 
(10 mM citric acid, 
pH 6.0, 0.05% 
tween) 
5% Donkey 
serum (Sigma) 
Rabbit polyclonal 
to amylase (1:100, 
Sigma A8273) 
overnight at 4°C  
Donkey anti-rabbit 
(1:200, Jackson labs, 
Alexa Fluor 594) 1 
hour at room 
temperature 
YFP Autoclaving for 15 
min at 121°C in 
citric acid buffer 
(10 mM citric acid, 
pH 6.0, 0.05% 
tween) 
5% Donkey 
serum (Sigma) 
Goat polyclonal to 
GFP (1:200, Abcam 
ab6673) overnight 
at 4°C 
Donkey anti-goat 
(1:200, Jackson labs, 
Alexa Fluor 488) 1 
hour at room 
temperature 
IGF2 Digestion with 1% 
pronase (Protease 
from 
Streptomyces 
griseus, Sigma 
Aldrich P6911) in 
1xPBS for 10 min 
at 37°C 
15% Donkey 
serum (Sigma) 
Goat anti-human 
IGF2 (1:50, R&D 
systems AF-292) 
overnight at 4°C 
Donkey anti-goat 
(1:200, Jackson labs, 
Alexa Fluor 488) 1 
hour at room 
temperature 
Cytokeratin Autoclaving for 15 
min at 121°C in 
citric acid buffer 
(10 mM citric acid, 
pH 6.0, 0.05% 
tween) 
15% Donkey 
serum (Sigma) 
Rabbit anti-
cytokeratin (1:500, 
Dako) overnight at 
4°C 
Donkey anti-rabbit 
(1:200, Jackson labs, 
Alexa Fluor 594) 1 
hour at room 
temperature 
CD31 Autoclaving for 15 
min at 121°C in 
citric acid buffer 
(10 mM citric acid, 
pH 6.0, 0.05% 
tween) 
15% Donkey 
serum (Sigma) 
Rabbit anti-CD31 
(1:50, Abcam 
ab28364) 
overnight at 4°C 
Donkey anti-rabbit 
(1:200, Jackson labs, 
Alexa Fluor 594) 1 
hour at room 
temperature 
Insulin Not needed 3% H2O2 30 min 
at room 
temperature, 
then rabbit 
serum (Dako) 
Polyclonal guinea-
pig anti-swine 
insulin antibody, 
(1:50, Dako A0564) 
90 min at room 
temperature 
Rabbit anti-guinea pig 
HRP coupled (1:100, 
Abcam ab6771) 1 
hour at room 
temperature, then 
DAB for 2 min 
 
 
 
 
 
 
 
 
 
55 
 
S4 Table. Primers/assays used for qRT-PCR. 
 
Gene Forward primer (5’ to 3’) Reverse primer (5’ to 3’) Amplicon 
(bp) 
Ppia AAGGGTTCCTCCTTTCACAGAA GATGCCAGGACCTGTATGCTT 146 
Igf2 AGTCCGAGAGGGACGTGTCTA CGGACTGTCTCCAGGTGTCAT 102 
H19 GTGTCACCAGAAGGGGAGTG AGTGCCTCATGGGAATGGTG 110 
Igf2r GGAAGACACCAGAACCAGACA TGACACTCATCCTCTGGAAGC 103 
Dlk1 GGACGGGAAATTCTGCGAAAT TTTCCAGAGAACCCAGGTGTG 126 
Plagl1 CTGGCTTTCCTGCTCTCACA AGCCCAGACAGAAAGAAGGTG 127 
Mest GCTCTGCACTCATGGAAGACT AGCACAACTATCTCAGGGCTT 107 
Pnliprp1 CCTTGGAGCCCTGAGAAGATC CCTCAATGGTCGATGGGTCAG 103 
Try GATTCCTGCCAGGGTGACTC TAGTTGCAGACCTTGGTGT 125  
Amy2 GCAAGTGGAATGGCGAGAAG TCGCTGATTATCATGGTTGTCC 110 
Sema5b GTGTTCGGCCTATCATAGC CAGGTTGTGATGTTCTGGATCC 139 
Sfrp1 GTCAGAGGCCATCATTGAACAT TGTCACCGTTTTCCTTCTTCAC 86 
mmu-miR-483-3p TM002560 (Applied Biosystems) 
snoRNA202 TM001232 (Applied Biosystems) 
snoRNA234 TM001234 (Applied Biosystems) 
 
